How many Cemiplimab clinical trials are there?

198 Cemiplimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 84 are actively recruiting participants. 23 are marked completed.

Are Cemiplimab clinical trials recruiting in 2026?

Yes — 84 Cemiplimab trials are actively recruiting in 2026, with 937 U.S. sites across 49 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Cemiplimab being studied for?

Cemiplimab is being studied for Cutaneous Squamous Cell Carcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer and 382 more. The trials are grouped by indication on this page.

What phase is Cemiplimab in?

Cemiplimab clinical trials span 11 Phase 3, 101 Phase 2, 37 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Cemiplimab clinical trials?

The lead sponsor across the most Cemiplimab trials is Regeneron Pharmaceuticals, with 100 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Cemiplimab Clinical Trials (2026): 198 Studies for Cutaneous Squamous Cell Carcinoma & Melanoma

Creator: Hipa.ai Research
Published: 2026-05-14T21:42:29.215Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

198 Cemiplimab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 139 indications (including Cutaneous Squamous Cell Carcinoma & Melanoma) and 31,597 total planned enrollment. 11 Phase 3 Cemiplimab trials and 101 Phase 2 are listed. 106 Cemiplimab clinical trials are actively recruiting at 937 U.S. sites across 49 states. Most recent activity: NCT07050186 (Nov 2035).

Where to Participate: All Cemiplimab Trial Sites in the U.S. (937 sites across 49 states)

Every actively recruiting Cemiplimabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	The University of Alabama at Birmingham	Birmingham35233	NCT06787612	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT01042379	Map
AL	University of Alabama_6th Ave	Birmingham35294	NCT03564340	Map
AL	Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis	Daphne36526	NCT06616584	Map
AL	Thomas Hospital	Fairhope36532	NCT06616584	Map
AL	Mobile Infirmary Medical Center	Mobile36607	NCT06616584	Map
AL	Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland	Saraland36571	NCT06616584	Map
AK	Katmai Oncology Group	Anchorage99508	NCT06616584	Map
AZ	Pioneer Research Center, LLC	Bullhead City86442	NCT06463665	Map
AZ	Ironwood Cancer & Research Centers	Chandler85224	NCT06246916	Map
AZ	Banner MD Anderson Cancer Center	Gilbert85234	NCT03972657	Map
AZ	Banner MD Anderson Cancer Center	Gilbert85234	NCT06246916	Map
AZ	Mayo Clinic	Phoenix85054	NCT03972657	Map
AZ	Medical Dermatology Specialists - Phoenix	Phoenix85006	NCT06585410	Map
AZ	Mayo Clinic - Arizona	Scottsdale85259	NCT06585410	Map
AZ	Mayo Clinic in Arizona	Scottsdale85259	NCT03017820	Map
AZ	Mayo Clinic in Arizona	Scottsdale85259	NCT06508463	Map
AZ	Banner University Medical Center - Tucson	Tucson85719	NCT06616584	Map
AZ	Banner University Medical Center - Tucson	Tucson85719	NCT07195734	Map
AZ	University of Arizona	Tucson85724	NCT03972657	Map
AZ	University of Arizona Cancer Center	Tucson85719	NCT06585410	Map
AZ	University of Arizona Cancer Center-North Campus	Tucson85719	NCT06616584	Map
AZ	University of Arizona Cancer Center-North Campus	Tucson85719	NCT07195734	Map
AR	NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro	Jonesboro72401	NCT06616584	Map
AR	University of Arkansas for Medical Sciences	Little Rock72205	NCT06246916	Map
AR	Arkansas Research Trials	North Little Rock72117	NCT06585410	Map
CA	Kaiser Permanente-Anaheim	Anaheim92806	NCT06616584	Map
CA	Kaiser Permanente-Baldwin Park	Baldwin Park91706	NCT06616584	Map
CA	Kaiser Permanente-Bellflower	Bellflower90706	NCT06616584	Map
CA	Tower Cancer Research Foundation	Beverly Hills90211	NCT06616584	Map
CA	Enloe Medical Center	Chico95926	NCT06616584	Map
CA	University of California - Davis, Comprehensive Cancer Center	Davis95817	NCT01042379	Map
CA	City of Hope	Duarte91010	NCT01042379	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT04590326	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06616584	Map
CA	City of Hope Medical Center	Duarte91010	NCT06860815	Map
CA	Site-113	Duarte91010	NCT06384807	Map
CA	Kaiser Permanente-Fontana	Fontana92335	NCT06616584	Map
CA	Kaiser Permanente Fresno Orchard Plaza	Fresno93720	NCT06616584	Map
CA	Kaiser Permanente-Fresno	Fresno93720	NCT06616584	Map
CA	Providence Medical Foundation	Fullerton92835	NCT06246916	Map
CA	Kaiser Permanente South Bay	Harbor City90710	NCT06616584	Map
CA	City of Hope at Irvine Lennar	Irvine92618	NCT06616584	Map
CA	Kaiser Permanente-Irvine	Irvine92618	NCT06616584	Map
CA	The City of Hope Orange County Lennar Foundation Cancer Center	Irvine92618	NCT04590326	Map
CA	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care	Irvine92612	NCT06980038	Map
CA	Scripps Clinic Torrey Pines	La Jolla92037	NCT05137054	Map
CA	Site-112	La Jolla92093	NCT06384807	Map
CA	UC San Diego Health	La Jolla92037	NCT06787612	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT06585410	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT06616584	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT06900595	Map
CA	University of California San Diego	La Jolla92093-0698	NCT01042379	Map
CA	University of California, San Diego	La Jolla92093	NCT06790602	Map
CA	City of Hope Antelope Valley	Lancaster93534	NCT06616584	Map
CA	Loma Linda University Medical Center	Loma Linda92354	NCT06616584	Map
CA	Cancer and Blood Specialty Clinic	Los Alamitos90720	NCT06246916	Map
CA	Cedars Sinai Medical Center	Los Angeles90048	NCT06787612	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT06594991	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT06616584	Map
CA	Kaiser Permanente Los Angeles Medical Center	Los Angeles90027	NCT06616584	Map
CA	Kaiser Permanente West Los Angeles	Los Angeles90034	NCT06616584	Map
CA	The Angeles Clinic and Research Institute	Los Angeles90025	NCT06121180	Map
CA	University of California Los Angeles	Los Angeles90024	NCT06246916	Map
CA	University of California Los Angeles (UCLA) Medical Center	Los Angeles90095	NCT04626635	Map
CA	University of Southern California	Los Angeles90033	NCT01042379	Map
CA	USC / Norris Comprehensive Cancer Center	Los Angeles90033	NCT07195734	Map
CA	USC Norris Comprehensive Cancer Center	Los Angeles90089	NCT06413680	Map
CA	Valkyrie Clinical Trials	Los Angeles90067	NCT04626635	Map
CA	Fremont - Rideout Cancer Center	Marysville95901	NCT06616584	Map
CA	Mather Veteran Affairs Medical Center	Mather95655	NCT06616584	Map
CA	HOAG Memorial Hospital Presbyterian	Newport Beach92663	NCT01042379	Map
CA	Kaiser Permanente-Oakland	Oakland94611	NCT06616584	Map
CA	Profound Research, Dermatology Medical Group - Oceanside	Oceanside92056	NCT06585410	Map
CA	Kaiser Permanente-Ontario	Ontario91761	NCT06616584	Map
CA	Chao Family Comprehensive Cancer Center	Orange92868	NCT04590326	Map
CA	St. Joseph Hospital Orange	Orange92868	NCT06246916	Map
CA	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange92868	NCT06980038	Map
CA	University of California Irvine	Orange92868	NCT06465329	Map
CA	University of California Irvine, UCI Medical Center	Orange92868	NCT06246916	Map
CA	Site-111	Palo Alto94304	NCT06384807	Map
CA	Kaiser Permanente - Panorama City	Panorama City91402	NCT06616584	Map
CA	Eisenhower Medical Center	Rancho Mirage92270	NCT06616584	Map
CA	Emad Ibrahim, MD, Inc.	Redlands92373	NCT06246916	Map
CA	Stanford University	Redwood City94063	NCT06585410	Map
CA	Kaiser Permanente-Riverside	Riverside92505	NCT06616584	Map
CA	Kaiser Permanente-Roseville	Roseville95661	NCT06616584	Map
CA	Kaiser Permanente Downtown Commons	Sacramento95814	NCT06616584	Map
CA	Sutter Health	Sacramento95816	NCT06246916	Map
CA	Sutter Medical Center Sacramento	Sacramento95816	NCT07195734	Map
CA	University of California Davis Comprehensive Cancer Center	Sacramento95817	NCT06616584	Map
CA	Kaiser Permanente-San Diego Zion	San Diego92120	NCT06616584	Map
CA	Kaiser Permanente-San Francisco	San Francisco94115	NCT06616584	Map
CA	The Regents of the University of California, San Francisco	San Francisco94118	NCT04626635	Map
CA	University of California San Francisco (UCSF)	San Francisco94115	NCT01042379	Map
CA	University of California San Francisco (UCSF)	San Francisco94143	NCT06246916	Map
CA	University of California San Francisco (UCSF)	San Francisco94143	NCT06413680	Map
CA	Veterans Affairs Medical Center - San Francisco	San Francisco94121	NCT06616584	Map
CA	Kaiser Permanente-Santa Teresa-San Jose	San Jose95119	NCT06616584	Map
CA	Kaiser Permanente San Leandro	San Leandro94577	NCT06616584	Map
CA	Kaiser Permanente-San Marcos	San Marcos92078	NCT06616584	Map
CA	Mills Health Center	San Mateo94401	NCT06616584	Map
CA	Kaiser San Rafael-Gallinas	San Rafael94903	NCT06616584	Map
CA	Sansum Clinic	Santa Barbara93105	NCT06246916	Map
CA	Kaiser Permanente Medical Center - Santa Clara	Santa Clara95051	NCT06616584	Map
CA	John Wayne Cancer Institute (JWCI)	Santa Monica90404	NCT03972657	Map
CA	St John's Cancer Institute	Santa Monica90404	NCT06246916	Map
CA	Kaiser Permanente-South San Francisco	South San Francisco94080	NCT06616584	Map
CA	Stanford University (Data Collection Only)	Stanford94305	NCT06594991	Map
CA	Cedars-Sinai Cancer - Tarzana	Tarzana91356	NCT06616584	Map
CA	City of Hope South Bay	Torrance90503	NCT06616584	Map
CA	Torrance Memorial Physician Network - Cancer Care	Torrance90505	NCT06616584	Map
CA	Gene Upshaw Memorial Tahoe Forest Cancer Center	Truckee96161	NCT06616584	Map
CA	City of Hope Upland	Upland91786	NCT06616584	Map
CA	Kaiser Permanente-Vallejo	Vallejo94589	NCT06616584	Map
CA	Peak Dermatology, Aesthetics and Wellness	Visalia93291	NCT06585410	Map
CA	Kaiser Permanente-Walnut Creek	Walnut Creek94596	NCT06616584	Map
CA	Kaiser Permanente-Woodland Hills	Woodland Hills91367	NCT06616584	Map
CO	Rocky Mountain Regional VA Medical Center	Aurora80045	NCT06246916	Map
CO	UCHealth University of Colorado Hospital	Aurora80045	NCT06900595	Map
CO	University of Colorado Cancer Center	Aurora80045	NCT01042379	Map
CO	University of Colorado Cancer Center	Aurora80045	NCT06246916	Map
CO	University of Colorado Hospital - Anschutz Cancer Pavilion - Lung Cancer Clinic	Aurora80045	NCT04626635	Map
CO	Sarah Cannon Research Institute (SCRI)	Denver80218	NCT03972657	Map
CO	The Melanoma And Skin Cancer Institute	Englewood80113	NCT06246916	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT06616584	Map
CT	Smilow Cancer Hospital Care Center-Fairfield	Fairfield06824	NCT06616584	Map
CT	Smilow Cancer Hospital Care Center at Greenwich	Greenwich06830	NCT06616584	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT06616584	Map
CT	Hartford Healthcare Alliance (Data Collection Only)	Hartford06102	NCT06594991	Map
CT	Yale Cancer Center	New Haven06510	NCT01042379	Map
CT	Yale Cancer Center	New Haven06510	NCT06246916	Map
CT	Yale University	New Haven06520-8032	NCT04291105	Map
CT	Yale University	New Haven06520	NCT06616584	Map
CT	Yale University Hospital	New Haven06510	NCT03972657	Map
CT	Yale School of Medicine	North Haven06473	NCT06413680	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT06616584	Map
CT	Smilow Cancer Hospital Care Center at Long Ridge	Stamford06902	NCT06616584	Map
CT	Smilow Cancer Hospital-Torrington Care Center	Torrington06790	NCT06616584	Map
CT	Smilow Cancer Hospital Care Center-Trumbull	Trumbull06611	NCT06616584	Map
CT	Smilow Cancer Hospital-Waterbury Care Center	Waterbury06708	NCT06616584	Map
CT	Smilow Cancer Hospital Care Center - Waterford	Waterford06385	NCT06616584	Map
DE	Beebe South Coastal Health Campus	Millville19967	NCT06616584	Map
DE	Helen F Graham Cancer Center	Newark19713	NCT06616584	Map
DE	Medical Oncology Hematology Consultants PA	Newark19713	NCT06616584	Map
DE	Beebe Health Campus	Rehoboth Beach19971	NCT06616584	Map
DC	George Washington University Medical Faculty Associates	Washington D.C.20037	NCT06585410	Map
DC	Georgetown University Medical Center	Washington D.C.20007	NCT01042379	Map
DC	Kaiser Permanente-Capitol Hill Medical Center	Washington D.C.20002	NCT06616584	Map
DC	Lombardi Comprehensive Cancer Center, Georgetown University	Washington D.C.20007	NCT06449313	Map
DC	Site-114	Washington D.C.20016	NCT06384807	Map
FL	Clermont Oncology Center	Clermont34711	NCT06246916	Map
FL	Clermont Oncology Center	Clermont34711	NCT06463665	Map
FL	Life Clinical Trials	Coral Springs33071	NCT06585410	Map
FL	Oncology & Hematology Associates of West Broward	Coral Springs33065	NCT06463665	Map
FL	Dermatology Associates of the Palm Beaches	Delray Beach33445	NCT06585410	Map
FL	Helios Clinical Research	Fort Lauderdale33316	NCT06463665	Map
FL	Malcom Randall Veterans Administration Medical Center	Gainesville32610	NCT06616584	Map
FL	University of Florida	Gainesville32611	NCT07058012	Map
FL	University of Florida Health	Gainesville32608	NCT04626635	Map
FL	Bioresearch Partner	Hialeah33013	NCT06463665	Map
FL	Cancer Specialist of North Florida	Jacksonville32256	NCT06246916	Map
FL	Mayo Clinic Florida	Jacksonville32224	NCT06246916	Map
FL	Mayo Clinic Jacksonville	Jacksonville32224	NCT03972657	Map
FL	Mayo Clinic Jacksonville	Jacksonville32224	NCT06787612	Map
FL	Bioresearch Partner	Miami33155	NCT06463665	Map
FL	Miami Cancer Institute at Baptist Health	Miami33176	NCT05317858	Map
FL	Site-103	Miami33176	NCT06384807	Map
FL	University of Miami - Sylvester Comprehensive Cancer Center	Miami33136	NCT06463665	Map
FL	University of Miami Sylvester Comprehensive Cancer Center	Miami33136	NCT06787612	Map
FL	Mid Florida Hematology and Oncology Center	Orange City32763	NCT06463665	Map
FL	Advent Health Cancer Institute	Orlando32804	NCT06787612	Map
FL	Orlando Health	Orlando32806	NCT06769698	Map
FL	Site-105	Orlando32827	NCT06384807	Map
FL	BRCR Medical Center, Inc.	Plantation33322	NCT06463665	Map
FL	Boca Raton Clinical Research (BRCR) Global	Tamarac33321	NCT06246916	Map
FL	H. Lee Moffitt Cancer Center	Tampa33612	NCT06246916	Map
FL	H. Lee Moffitt Cancer Center and Research Institute	Tampa33612	NCT01042379	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05317858	Map
FL	Moffitt Cancer Center	Tampa33612	NCT04975152	Map
FL	Moffitt Cancer Center	Tampa33612	NCT01042379	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06121180	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06616584	Map
FL	Moffitt Cancer Center - McKinley Drive	Tampa33612	NCT03972657	Map
FL	Site-115	Tampa33612	NCT06384807	Map
FL	Tampa General Hospital Cancer Institute	Tampa33606	NCT06787612	Map
FL	University of South Florida	Tampa33612	NCT06585410	Map
GA	University Cancer & Blood Center	Athens30607	NCT06246916	Map
GA	Emory Proton Therapy Center	Atlanta30308	NCT07195734	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT06616584	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06616584	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06731270	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06980038	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT07195734	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT06616584	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT06731270	Map
GA	Emory University School of Medicine	Atlanta30308	NCT06769698	Map
GA	Emory University/Winship Cancer Institute	Atlanta30322	NCT04428671	Map
GA	Grady Health System	Atlanta30303	NCT06616584	Map
GA	Northside Hospital	Atlanta30342	NCT06616584	Map
GA	Winship Cancer Institute of Emory University	Atlanta30322	NCT01042379	Map
GA	Winship Cancer Institute of Emory University	Atlanta30004	NCT05137054	Map
GA	Site-110	Augusta30912	NCT06384807	Map
GA	Atlanta VA Medical Center	Decatur30033	NCT06616584	Map
GA	Northside Hospital - Duluth	Duluth30096	NCT06616584	Map
GA	Northeast Georgia Medical Center-Gainesville	Gainesville30501	NCT06616584	Map
GA	Emory Johns Creek Hospital	Johns Creek30097	NCT06616584	Map
GA	Northside Hospital - Gwinnett	Lawrenceville30046	NCT06616584	Map
GA	Lewis Cancer and Research Pavilion at Saint Joseph's/Candler	Savannah31405	NCT06616584	Map
ID	Saint Alphonsus Cancer Care Center-Boise	Boise83706	NCT06616584	Map
ID	Saint Luke's Cancer Institute - Boise	Boise83712	NCT06616584	Map
ID	Saint Alphonsus Cancer Care Center-Caldwell	Caldwell83605	NCT06616584	Map
ID	Beacon Clinic	Coeur d'Alene83815	NCT06246916	Map
ID	Kootenai Health - Coeur d'Alene	Coeur d'Alene83814	NCT06616584	Map
ID	Saint Luke's Cancer Institute - Fruitland	Fruitland83619	NCT06616584	Map
ID	Idaho Urologic Institute-Meridian	Meridian83642	NCT06616584	Map
ID	Saint Luke's Cancer Institute - Meridian	Meridian83642	NCT06616584	Map
ID	Saint Alphonsus Cancer Care Center-Nampa	Nampa83687	NCT06616584	Map
ID	Saint Luke's Cancer Institute - Nampa	Nampa83687	NCT06616584	Map
ID	Kootenai Clinic Cancer Services - Post Falls	Post Falls83854	NCT06616584	Map
ID	Kootenai Clinic Cancer Services - Sandpoint	Sandpoint83864	NCT06616584	Map
IL	Advocate Outpatient Center - Aurora	Aurora60506	NCT06616584	Map
IL	Advocate Good Shepherd Hospital	Barrington60010	NCT06616584	Map
IL	Illinois CancerCare-Bloomington	Bloomington61704	NCT06616584	Map
IL	Illinois CancerCare-Canton	Canton61520	NCT06616584	Map
IL	Illinois CancerCare-Carthage	Carthage62321	NCT06616584	Map
IL	Advocate Illinois Masonic Medical Center	Chicago60657	NCT06616584	Map
IL	Lurie Children's Hospital-Chicago	Chicago60611	NCT06900595	Map
IL	Northwestern University	Chicago60611	NCT06616584	Map
IL	Northwestern University	Chicago60611	NCT06900595	Map
IL	Northwestern University	Chicago60611	NCT07050186	Map
IL	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	Chicago60611	NCT04590326	Map
IL	Rush MD Anderson Cancer Center	Chicago60612	NCT07195734	Map
IL	University of Chicago	Chicago60453	NCT01042379	Map
IL	University of Chicago	Chicago60637	NCT06413680	Map
IL	University of Chicago	Chicago60637	NCT06787612	Map
IL	University of Chicago Medical Center	Chicago60637	NCT04590326	Map
IL	University of Chicago Medical Center	Chicago60637	NCT06121180	Map
IL	University of Chicago Medical Center	Chicago60637	NCT06585410	Map
IL	University of Illinois Cancer Center	Chicago60612	NCT04626635	Map
IL	AMG Crystal Lake - Oncology	Crystal Lake60014	NCT06616584	Map
IL	Carle at The Riverfront	Danville61832	NCT06616584	Map
IL	Carle at The Riverfront	Danville61832	NCT06900595	Map
IL	Cancer Care Specialists of Illinois - Decatur	Decatur62526	NCT06616584	Map
IL	Decatur Memorial Hospital	Decatur62526	NCT06616584	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT06616584	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT06900595	Map
IL	Illinois CancerCare-Dixon	Dixon61021	NCT06616584	Map
IL	Advocate Good Samaritan Hospital	Downers Grove60515	NCT06616584	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT06616584	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT06900595	Map
IL	Crossroads Cancer Center	Effingham62401	NCT06616584	Map
IL	Advocate Sherman Hospital	Elgin60123	NCT06616584	Map
IL	Illinois CancerCare-Eureka	Eureka61530	NCT06616584	Map
IL	Illinois CancerCare-Galesburg	Galesburg61401	NCT06616584	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT06616584	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT06900595	Map
IL	Northwestern Medicine Glenview Outpatient Center	Glenview60026	NCT06616584	Map
IL	Northwestern Medicine Glenview Outpatient Center	Glenview60026	NCT06900595	Map
IL	Northwestern Medicine Grayslake Outpatient Center	Grayslake60030	NCT06616584	Map
IL	Northwestern Medicine Grayslake Outpatient Center	Grayslake60030	NCT06900595	Map
IL	Advocate South Suburban Hospital	Hazel Crest60429	NCT06616584	Map
IL	Hope and Healing Cancer Services	Hinsdale60521	NCT06246916	Map
IL	Illinois CancerCare-Kewanee Clinic	Kewanee61443	NCT06616584	Map
IL	Northwestern Medicine Lake Forest Hospital	Lake Forest60045	NCT06616584	Map
IL	Northwestern Medicine Lake Forest Hospital	Lake Forest60045	NCT06900595	Map
IL	AMG Libertyville - Oncology	Libertyville60048	NCT06616584	Map
IL	Condell Memorial Hospital	Libertyville60048	NCT06616584	Map
IL	Illinois CancerCare-Macomb	Macomb61455	NCT06616584	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT06616584	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT06900595	Map
IL	Loyola University	Maywood60153	NCT01042379	Map
IL	Loyola University Medical Center	Maywood60153	NCT06616584	Map
IL	Oak Dermatology	Naperville60563	NCT06585410	Map
IL	Carle BroMenn Medical Center	Normal61761	NCT06616584	Map
IL	Carle BroMenn Medical Center	Normal61761	NCT06900595	Map
IL	Carle Cancer Institute Normal	Normal61761	NCT06616584	Map
IL	Carle Cancer Institute Normal	Normal61761	NCT06900595	Map
IL	Cancer Care Center of O'Fallon	O'Fallon62269	NCT06616584	Map
IL	HSHS Saint Elizabeth's Hospital	O'Fallon62269	NCT06616584	Map
IL	Northwestern Medicine Oak Brook	Oak Brook60523	NCT06616584	Map
IL	Northwestern Medicine Oak Brook	Oak Brook60523	NCT06900595	Map
IL	Advocate Christ Medical Center	Oak Lawn60453-2699	NCT06616584	Map
IL	Advocate Outpatient Center - Oak Lawn	Oak Lawn60453	NCT06616584	Map
IL	Northwestern Medicine Orland Park	Orland Park60462	NCT06616584	Map
IL	Northwestern Medicine Orland Park	Orland Park60462	NCT06900595	Map
IL	Illinois CancerCare-Ottawa Clinic	Ottawa61350	NCT06616584	Map
IL	Advocate High Tech Medical Park	Palos Heights60463	NCT06616584	Map
IL	Advocate Lutheran General Hospital	Park Ridge60068	NCT06246916	Map
IL	Advocate Lutheran General Hospital	Park Ridge60068	NCT06616584	Map
IL	Illinois CancerCare-Pekin	Pekin61554	NCT06616584	Map
IL	Illinois CancerCare	Peoria61615	NCT06246916	Map
IL	Illinois CancerCare-Peoria	Peoria61615	NCT06616584	Map
IL	Illinois CancerCare-Peru	Peru61354	NCT06616584	Map
IL	Illinois CancerCare-Princeton	Princeton61356	NCT06616584	Map
IL	Memorial Hospital East	Shiloh62269	NCT06616584	Map
IL	Memorial Hospital East	Shiloh62269	NCT06900595	Map
IL	Orchard Healthcare Research Inc.	Skokie60077	NCT06465329	Map
IL	Southern Illinois University School of Medicine	Springfield62702	NCT06616584	Map
IL	Springfield Clinic	Springfield62702	NCT06616584	Map
IL	Springfield Memorial Hospital	Springfield62781	NCT06616584	Map
IL	Carle Cancer Center	Urbana61801	NCT06616584	Map
IL	Carle Cancer Center	Urbana61801	NCT06900595	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT06616584	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT06900595	Map
IL	Illinois CancerCare - Washington	Washington61571	NCT06616584	Map
IN	Fort Wayne Medical Oncology and Hematology	Fort Wayne46825	NCT06246916	Map
IN	Indiana University Health Simon Cancer Center	Indianapolis46202	NCT05137054	Map
IN	Indiana University/Melvin and Bren Simon Cancer Center	Indianapolis46202	NCT06616584	Map
IN	Richard L. Roudebush Veterans Affairs Medical Center	Indianapolis46202	NCT06616584	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT06900595	Map
IA	UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny50023	NCT07195734	Map
IA	Saint Anthony Regional Hospital	Carroll51401	NCT06900595	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT06900595	Map
IA	UI Health Care Mission Cancer and Blood - West Des Moines Clinic	Clive50325	NCT07195734	Map
IA	Broadlawns Medical Center	Des Moines50314	NCT06900595	Map
IA	Broadlawns Medical Center	Des Moines50314	NCT07195734	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT06900595	Map
IA	Iowa Methodist Medical Center	Des Moines50309	NCT07195734	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT06900595	Map
IA	Mercy Medical Center - Des Moines	Des Moines50314	NCT07195734	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT06900595	Map
IA	UI Health Care Mission Cancer and Blood - Des Moines Clinic	Des Moines50309	NCT07195734	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT06900595	Map
IA	UI Health Care Mission Cancer and Blood - Laurel Clinic	Des Moines50314	NCT07195734	Map
IA	UI Healthcare Mission Cancer and Blood - Fort Dodge	Fort Dodge50501	NCT06900595	Map
IA	University of Iowa Health Care	Iowa City52242	NCT07404332	Map
IA	University of Iowa Hospitals and Clinics	Iowa City52242	NCT04626635	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT06900595	Map
IA	UI Health Care Mission Cancer and Blood - Waukee Clinic	Waukee50263	NCT07195734	Map
KS	University of Kansas Clinical Research Center	Fairway66205	NCT06616584	Map
KS	HaysMed	Hays67601	NCT06616584	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT06616584	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT07195734	Map
KS	Lawrence Memorial Hospital	Lawrence66044	NCT06616584	Map
KS	Veteran Administration Eastern Kansas Healthcare	Leavenworth66048	NCT06616584	Map
KS	The University of Kansas Cancer Center - Olathe	Olathe66061	NCT06616584	Map
KS	University of Kansas Cancer Center-Overland Park	Overland Park66210	NCT06616584	Map
KS	University of Kansas Cancer Center-Overland Park	Overland Park66210	NCT07195734	Map
KS	University of Kansas Hospital-Indian Creek Campus	Overland Park66211	NCT06616584	Map
KS	Salina Regional Health Center	Salina67401	NCT06616584	Map
KS	University of Kansas Health System Saint Francis Campus	Topeka66606	NCT06616584	Map
KS	The University of Kansas Cancer Center	Westwood66205	NCT06246916	Map
KS	The University of Kansas Cancer Center	Westwood66205	NCT06787612	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT06616584	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT07195734	Map
KY	Equity Medical, LLC	Bowling Green42104	NCT06585410	Map
KY	St. Elizabeth Healthcare	Edgewood41017	NCT06769698	Map
KY	Markey Cancer Center Clinical Research Organization	Lexington40536	NCT06246916	Map
KY	University of Kentucky Chandler Medical Center	Lexington40536	NCT05142189	Map
KY	University of Kentucky/Markey Cancer Center	Lexington40536	NCT06616584	Map
KY	Norton Cancer Institute	Louisville40202	NCT05142189	Map
KY	Norton Cancer Institute	Louisville40202	NCT06769698	Map
KY	Norton Cancer Institute, St. Matthews Clinic	Louisville40207	NCT06787612	Map
LA	LSU Health Baton Rouge-North Clinic	Baton Rouge70805	NCT07195734	Map
LA	Mary Bird Perkins Cancer Center	Baton Rouge70809	NCT06246916	Map
LA	Our Lady of the Lake Physician Group	Baton Rouge70808	NCT07195734	Map
LA	Ochsner Clinic Foundation	New Orleans70121	NCT04291105	Map
LA	Ochsner Medical Center Jefferson	New Orleans70121	NCT06980038	Map
ME	Harold Alfond Center for Cancer Care	Augusta04330	NCT06616584	Map
ME	MaineHealth Waldo Hospital	Belfast04915	NCT06616584	Map
ME	Lafayette Family Cancer Center-EMMC	Brewer04412	NCT06616584	Map
ME	MaineHealth Cancer Care and IV Therapy - Brunswick	Brunswick04011	NCT06616584	Map
ME	MaineHealth LincolnHealth Hospital	Damariscotta04543	NCT06616584	Map
ME	Penobscot Bay Medical Center	Rockport04856	NCT06616584	Map
ME	MaineHealth Cancer Care Center of York County	Sanford04073	NCT06616584	Map
ME	MaineHealth Cancer Care and IV Therapy - South Portland	South Portland04106	NCT06616584	Map
MD	JHU Sidney Kimmel Comprehensive Cancer Center LAO	Baltimore21231	NCT07147231	Map
MD	Johns Hopkins Sidney Kimmel Comprehensive Cancer Center	Baltimore21287	NCT05142189	Map
MD	Johns Hopkins SKCCC	Baltimore21231	NCT06205836	Map
MD	Johns Hopkins University	Baltimore21287	NCT04988074	Map
MD	Kaiser Permanente-Woodlawn Medical Center	Baltimore21244	NCT06616584	Map
MD	Saint Agnes Hospital	Baltimore21229	NCT06616584	Map
MD	University of Maryland	Baltimore21201	NCT05317858	Map
MD	National Cancer Institute	Bethesda20892	NCT06171750	Map
MD	Maryland Oncology Hematology, P.A.	Columbia21044	NCT06246916	Map
MD	UPMC Western Maryland	Cumberland21502	NCT06616584	Map
MD	Kaiser Permanente-Gaithersburg Medical Center	Gaithersburg20879	NCT06616584	Map
MD	Kaiser Permanente - Largo Medical Center	Largo20774	NCT06616584	Map
MD	Kaiser Permanente Lutherville - Timonium Medical Center	Lutherville21093	NCT06616584	Map
MD	US Dermatology Partners DBA DermAssociates, PC	Rockville20850	NCT06585410	Map
MA	Beverly Hospital	Beverly01915	NCT06616584	Map
MA	Northeast Dermatology Associates	Beverly01915	NCT06585410	Map
MA	Dana Farber / Harvard Cancer Center	Boston02215	NCT03564340	Map
MA	Dana Farber Cancer Institute Brookline Avenue	Boston02215	NCT04590326	Map
MA	Dana Farber/Harvard Cancer Center	Boston02215	NCT05137054	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06585410	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06900595	Map
MA	Massachusetts General Hospital	Boston02114	NCT04590326	Map
MA	Massachusetts General Hospital	Boston02114	NCT03564340	Map
MA	Massachusetts General Hospital	Boston02114	NCT03972657	Map
MA	Massachusetts General Hospital	Boston02114	NCT06171750	Map
MA	Massachusetts General Hospital	Boston02114	NCT06469281	Map
MA	Massachusetts General Hospital	Boston02114	NCT06787612	Map
MA	Lahey Hospital and Medical Center	Burlington01805	NCT06616584	Map
MA	Addison Gilbert Hospital	Gloucester01930	NCT06616584	Map
MA	Lahey Medical Center-Peabody	Peabody01960	NCT06616584	Map
MA	Baystate Medical Center	Springfield01199	NCT06616584	Map
MA	UMass Memorial Medical Center - University Campus	Worcester01655	NCT06616584	Map
MI	University of Michigan	Ann Arbor48109	NCT06246916	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT06900595	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT07195734	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Brighton	Brighton48114	NCT06616584	Map
MI	University of Michigan - Brighton Center for Specialty Care	Brighton48116	NCT07195734	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Canton	Canton48188	NCT06616584	Map
MI	Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital	Chelsea48118	NCT06616584	Map
MI	Michigan Hematology and Oncology Consultants	Dearborn48126	NCT06463665	Map
MI	Henry Ford Cancer Institute/Henry Ford Health System	Detroit48202	NCT06246916	Map
MI	Henry Ford Hospital	Detroit48202	NCT07195734	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT04590326	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT05137054	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT06465329	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT06787612	Map
MI	Site-109	Detroit48201	NCT06384807	Map
MI	OSF Saint Francis Hospital and Medical Group	Escanaba49829	NCT06616584	Map
MI	Detroit Clinical Research Center	Farmington Hills48334	NCT06465329	Map
MI	Oakland Medical Group	Farmington Hills48336	NCT06463665	Map
MI	Cancer Hematology Centers - Flint	Flint48503	NCT06616584	Map
MI	Genesys Hurley Cancer Institute	Flint48503	NCT06616584	Map
MI	START Midwest - Cancer & Hematology Centers of Western Michigan, PC	Grand Rapids49546	NCT04626635	Map
MI	Start Midwest Cancer Research	Grand Rapids49546	NCT06413680	Map
MI	Herbert-Herman Cancer Center, Sparrow Hospital	Lansing48912	NCT01042379	Map
MI	University of Michigan Health - Sparrow Lansing	Lansing48912	NCT06616584	Map
MI	Trinity Health Saint Mary Mercy Livonia Hospital	Livonia48154	NCT06616584	Map
MI	MyMichigan Dermatologic Oncology	Midland48640	NCT06585410	Map
MI	Trinity Health Saint Joseph Mercy Oakland Hospital	Pontiac48341	NCT06616584	Map
MI	Somerset Skin Centre	Troy48084	NCT06585410	Map
MI	Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus	Ypsilanti48197	NCT06616584	Map
MN	Sanford Joe Lueken Cancer Center	Bemidji56601	NCT06616584	Map
MN	Essentia Health Saint Joseph's Medical Center	Brainerd56401	NCT06616584	Map
MN	Mercy Hospital	Coon Rapids55433	NCT06616584	Map
MN	Essentia Health - Deer River Clinic	Deer River56636	NCT06616584	Map
MN	Essentia Health Cancer Center	Duluth55805	NCT06616584	Map
MN	Fairview Southdale Hospital	Edina55435	NCT06616584	Map
MN	Minnesota Oncology Hematology, P.A	Fridley55432	NCT06246916	Map
MN	Essentia Health Hibbing Clinic	Hibbing55746	NCT06616584	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT06616584	Map
MN	Allina Health Cancer Institute	Minneapolis55407	NCT06246916	Map
MN	University of Minnesota	Minneapolis55455	NCT01042379	Map
MN	North Memorial Medical Health Center	Robbinsdale55422	NCT06616584	Map
MN	Mayo Clinic	Rochester55905	NCT04291105	Map
MN	Mayo Clinic	Rochester55905	NCT03972657	Map
MN	Mayo Clinic	Rochester55905	NCT01042379	Map
MN	Mayo Clinic	Rochester55905	NCT05137054	Map
MN	Mayo Clinic - Rochester	Rochester55901	NCT03564340	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT03017820	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT06508463	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT06918132	Map
MN	Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center	Saint Louis Park55416	NCT01042379	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT06616584	Map
MN	Regions Hospital	Saint Paul55101	NCT06616584	Map
MN	United Hospital	Saint Paul55102	NCT06616584	Map
MN	Essentia Health Sandstone	Sandstone55072	NCT06616584	Map
MN	Essentia Health Virginia Clinic	Virginia55792	NCT06616584	Map
MN	Minnesota Oncology Hematology PA-Woodbury	Woodbury55125	NCT06616584	Map
MN	Sanford Cancer Center Worthington	Worthington56187	NCT06616584	Map
MS	Baptist Memorial Hospital and Cancer Center-Golden Triangle	Columbus39705	NCT06616584	Map
MS	Baptist Cancer Center-Grenada	Grenada38901	NCT06616584	Map
MS	Gulfport Memorial Hospital	Gulfport39502	NCT06616584	Map
MS	Baptist Memorial Hospital and Cancer Center-Union County	New Albany38652	NCT06616584	Map
MS	Baptist Memorial Hospital and Cancer Center-Oxford	Oxford38655	NCT06616584	Map
MS	Baptist Memorial Hospital and Cancer Center-Desoto	Southhaven38671	NCT06616584	Map
MO	Saint Francis Medical Center	Cape Girardeau63703	NCT06616584	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT06616584	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT06900595	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT06616584	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT06900595	Map
MO	Parkland Health Center - Farmington	Farmington63640	NCT06616584	Map
MO	Children's Mercy Hospitals and Clinics	Kansas City64108	NCT06900595	Map
MO	Kansas City Veterans Affairs Medical Center	Kansas City64128	NCT06616584	Map
MO	University Health Truman Medical Center	Kansas City64108	NCT06616584	Map
MO	University of Kansas Cancer Center - Briarcliff	Kansas City64116	NCT06616584	Map
MO	University of Kansas Cancer Center - Briarcliff	Kansas City64116	NCT07195734	Map
MO	University of Kansas Cancer Center - North	Kansas City64154	NCT06616584	Map
MO	University of Kansas Cancer Center - North	Kansas City64154	NCT07195734	Map
MO	Dermatology and Skin Cancer Center	Lee's Summit64064	NCT06585410	Map
MO	University of Kansas Cancer Center - Lee's Summit	Lee's Summit64064	NCT06616584	Map
MO	University of Kansas Cancer Center - Lee's Summit	Lee's Summit64064	NCT07195734	Map
MO	Lake Regional Hospital	Osage Beach65065	NCT06616584	Map
MO	Sainte Genevieve County Memorial Hospital	Sainte Genevieve63670	NCT06616584	Map
MO	CoxHealth South Hospital	Springfield65807	NCT06900595	Map
MO	Mercy Hospital South	St Louis63128	NCT06616584	Map
MO	Mercy South	St Louis63128	NCT06246916	Map
MO	Missouri Baptist Medical Center	St Louis63131	NCT06616584	Map
MO	Site-101	St Louis63108	NCT06384807	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT06616584	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT06900595	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT06616584	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT06900595	Map
MO	VA St. Louis Healthcare System	St Louis63106	NCT06246916	Map
MO	Washington University	St Louis63110	NCT06246916	Map
MO	Washington University in St. Louis - Center for Dermatologic and Cosmetic Surgery	St Louis63141	NCT06585410	Map
MO	Washington University School of Medicine	St Louis63110	NCT06616584	Map
MO	Washington University School of Medicine	St Louis63110	NCT06900595	Map
MO	Washington University School of Medicine-Sitemen Cancer Center	St Louis63110	NCT06449313	Map
MO	Missouri Baptist Sullivan Hospital	Sullivan63080	NCT06616584	Map
MO	BJC Outpatient Center at Sunset Hills	Sunset Hills63127	NCT06616584	Map
MT	Community Hospital of Anaconda	Anaconda59711	NCT06616584	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT06616584	Map
MT	St. Vincent Healthcare	Billings59102	NCT06246916	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT06616584	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT06616584	Map
MT	Logan Health Medical Center	Kalispell59901	NCT06616584	Map
MT	Community Medical Center	Missoula59804	NCT06616584	Map
NE	Nebraska Medicine-Bellevue	Bellevue68123	NCT06900595	Map
NE	Nebraska Cancer Specialists/Oncology Hematology West PC - MECC	Omaha68114	NCT07195734	Map
NE	Nebraska Medicine-Village Pointe	Omaha68118	NCT06900595	Map
NE	Nebraska Methodist Hospital	Omaha68114	NCT07195734	Map
NE	Oncology Hematology West P.C. dba Nebraska Cancer Specialists	Omaha68130	NCT06246916	Map
NE	Oncology Hematology West P.C. dba Nebraska Cancer Specialists	Omaha68130	NCT06769698	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT06900595	Map
NV	Comprehensive Cancer Centers of Nevada	Las Vegas89148	NCT06246916	Map
NV	Las Vegas Dermatology	Las Vegas89144	NCT06585410	Map
NH	New Hampshire Oncology Hematology PA-Concord	Concord03301	NCT06616584	Map
NH	Dartmouth Hitchcock Medical Center	Lebanon03756	NCT06246916	Map
NH	Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center	Lebanon03756	NCT06616584	Map
NH	Solinsky Center for Cancer Care	Manchester03103	NCT06616584	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT06900595	Map
NJ	Memorial Sloan Kettering Basking Ridge (All Protocol Activities)	Basking Ridge07920	NCT06594991	Map
NJ	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites)	Basking Ridge07920	NCT06699602	Map
NJ	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT04722523	Map
NJ	Metropolitan Dermatology	Clark07066	NCT06585410	Map
NJ	Hackensack Meridian Health (Data Collection Only)	Hackensack07601	NCT06594991	Map
NJ	John Theurer Cancer Center	Hackensack07601	NCT06246916	Map
NJ	John Theurer Cancer Center Hackensack University Medical Center	Hackensack07601	NCT06469281	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT06900595	Map
NJ	Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown07748	NCT06594991	Map
NJ	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown07748	NCT04722523	Map
NJ	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown07748	NCT06699602	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT06900595	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT04722523	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT06594991	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT06699602	Map
NJ	Virtua Samson Cancer Center	Moorestown08057	NCT06616584	Map
NJ	Morristown Medical Center	Morristown07960	NCT06465329	Map
NJ	Inspira Medical Center Mullica Hill	Mullica Hill08062	NCT06463665	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08901	NCT04626635	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT01042379	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08901	NCT06246916	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08901	NCT06465329	Map
NJ	The Valley Hospital Inc.	Paramus07652	NCT06246916	Map
NJ	Virtua Voorhees	Voorhees Township08043	NCT06616584	Map
NM	University of New Mexico	Albuquerque87102	NCT06585410	Map
NM	University of New Mexico Cancer Center	Albuquerque87106	NCT06616584	Map
NY	New York Oncology Hematology	Albany12206	NCT06246916	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT01042379	Map
NY	Roswell Park Cancer Institute	Buffalo14203	NCT06469281	Map
NY	Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)	Commack11725	NCT04722523	Map
NY	Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)	Commack11725	NCT06699602	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT06900595	Map
NY	Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)	Commack11725	NCT06594991	Map
NY	Memorial Sloan Kettering West Harrison (Limited Protocol Activities)	Harrison10604	NCT06699602	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT06900595	Map
NY	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison10604	NCT06594991	Map
NY	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison10604	NCT04722523	Map
NY	Northwell Health	Lake Success11042	NCT06413680	Map
NY	Northwell Health Center for Advanced Medicine	New Hyde Park11042	NCT06121180	Map
NY	Columbia University - The Trustees of Columbia University in the City of New York	New York10032	NCT03972657	Map
NY	Columbia University Irving Medical Center	New York10032	NCT04543071	Map
NY	Columbia University Irving Medical Center	New York10032	NCT07433673	Map
NY	Columbia University Irving Medical Center/ New York Presbyterian Hospital	New York10032	NCT06571708	Map
NY	Columbia University Medical Center	New York10032	NCT03564340	Map
NY	Columbia University Medical Center	New York10032	NCT01042379	Map
NY	Columbia University Medical Center - Herbert Irving Center for Dermatology and Skin Cancer - Herbert Irving Pavilion	New York10032	NCT06585410	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT04291105	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT03972657	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06088771	Map
NY	Laura and Isaac Perlmutter Cancer Center / NYU Langone Health	New York10016	NCT01042379	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT04626635	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT04722523	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT04590326	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT03564340	Map
NY	Memorial Sloan Kettering Cancer Center	New York10021	NCT06585410	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06900595	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activites)	New York10065	NCT06699602	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT06594991	Map
NY	Montefiore Medical Center	New York10461	NCT03972657	Map
NY	New York Presbyterian Hospital Columbia University Medical Center	New York10032	NCT05137054	Map
NY	NYU Langone Health Perlmutter Cancer Center	New York10016	NCT03972657	Map
NY	Site-117	New York10021	NCT06384807	Map
NY	Weill Cornell Medicine	New York10065	NCT06623656	Map
NY	Weill Cornell Medicine/New York Presbyterian Hospital	New York10021	NCT05137054	Map
NY	University of Rochester	Rochester14642	NCT06616584	Map
NY	University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center) - Rochester	Rochester14642	NCT03972657	Map
NY	University of Rochester Wilmot Cancer Institute	Rochester14642	NCT01042379	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activites)	Rockville Centre11553	NCT04722523	Map
NY	James J Peters VA Medical Center	The Bronx10468	NCT06616584	Map
NY	Montefiore Einstein Comprehensive Cancer Center (MECCC)	The Bronx10461	NCT06865339	Map
NY	Montefiore Medical Center	The Bronx10467	NCT01042379	Map
NY	Montefiore Medical Center-Einstein Campus	The Bronx10461	NCT06616584	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT06900595	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale11553	NCT06594991	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale11553	NCT06699602	Map
NY	Rochester Dermatologic Surgery, P.C.	Victor14564	NCT06585410	Map
NY	Wilmot Cancer Institute at Webster	Webster14580	NCT06616584	Map
NC	Messino Cancer Center	Asheville28806	NCT06246916	Map
NC	Duke Cancer Center Cary	Cary27518	NCT06900595	Map
NC	UNC Hospitals Dermatology and Skin Cancer Center at Southern Village	Chapel Hill27516	NCT06585410	Map
NC	University of North Carolina at Chapel Hill	Chapel Hill27599	NCT05137054	Map
NC	University of North Carolina at Chapel Hill	Chapel Hill27514	NCT06413680	Map
NC	University of North Carolina at Chapel Hill	Chapel Hill27599	NCT06902376	Map
NC	Levine Cancer Institute	Charlotte28204	NCT06246916	Map
NC	Novant Health Cancer Institute	Charlotte28204	NCT06246916	Map
NC	Novant Health Weisiger Cancer Institute - Charlotte	Charlotte28204	NCT06246916	Map
NC	Duke Health System	Durham27710	NCT06246916	Map
NC	Duke University Medical Center	Durham27710	NCT06900595	Map
NC	Durham VA Medical Center	Durham27705	NCT06616584	Map
NC	FirstHealth of the Carolinas-Moore Regional Hospital	Pinehurst28374	NCT06616584	Map
NC	Duke Cancer Center Raleigh	Raleigh27609	NCT06900595	Map
NC	Novant Health Zimmer Cancer Institute - Wilmington	Wilmington28401	NCT06246916	Map
NC	Atrium Health Wake Forest Baptist	Winston-Salem27103	NCT05317858	Map
NC	Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem27157	NCT01042379	Map
NC	Wake Forest University Health Sciences	Winston-Salem27157	NCT05137054	Map
ND	Sanford Bismarck Medical Center	Bismarck58501	NCT06616584	Map
ND	Essentia Health Cancer Center-South University Clinic	Fargo58103	NCT06616584	Map
ND	Sanford Broadway Medical Center	Fargo58122	NCT06616584	Map
ND	Sanford Roger Maris Cancer Center	Fargo58122	NCT06616584	Map
OH	OhioHealth O'Bleness Hospital	Athens45701	NCT06616584	Map
OH	Aultman Health Foundation	Canton44710	NCT06616584	Map
OH	Gabrail Cancer and Research Center	Canton44718	NCT06463665	Map
OH	Miami Valley Hospital South	Centerville45459	NCT06616584	Map
OH	Oncology Hematology Care Clinical Trials	Cincinnati45242	NCT06246916	Map
OH	University of Cincinnati Medical Center	Cincinnati45219	NCT04626635	Map
OH	University of Cincinnati Medical Center	Cincinnati45219	NCT04291105	Map
OH	Cleveland Clinic	Cleveland44106	NCT01042379	Map
OH	Cleveland Clinic	Cleveland44195	NCT06585410	Map
OH	Seidman Cancer Center	Cleveland44106	NCT06246916	Map
OH	Columbus Oncology and Hematology Associates Inc	Columbus43214	NCT06616584	Map
OH	Doctors Hospital	Columbus43228	NCT06616584	Map
OH	Grant Medical Center	Columbus43215	NCT06616584	Map
OH	Ohio State University	Columbus43210	NCT06769698	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06528769	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06900595	Map
OH	Ohio State University Comprehensive Cancer Center LAO	Columbus43210	NCT07281417	Map
OH	Riverside Methodist Hospital	Columbus43214	NCT06616584	Map
OH	The Ohio State University James Cancer Hospital	Columbus43210	NCT05137054	Map
OH	The Ohio State University Wexner Medical Center	Columbus43210	NCT04590326	Map
OH	The Ohio State University Wexner Medical Center	Columbus43210	NCT06246916	Map
OH	The Ohio State University, Stefanie Spielman Comprehensive Breast Center	Columbus43212	NCT01042379	Map
OH	Miami Valley Hospital	Dayton45409	NCT06616584	Map
OH	Miami Valley Hospital North	Dayton45415	NCT06616584	Map
OH	Premier Blood and Cancer Center	Dayton45409	NCT06616584	Map
OH	Delaware Health Center-Grady Cancer Center	Delaware43015	NCT06616584	Map
OH	Grady Memorial Hospital	Delaware43015	NCT06616584	Map
OH	Columbus Oncology and Hematology Associates	Dublin43016	NCT06616584	Map
OH	Dublin Methodist Hospital	Dublin43016	NCT06616584	Map
OH	Atrium Medical Center-Middletown Regional Hospital	Franklin45005-1066	NCT06616584	Map
OH	Miami Valley Cancer Care and Infusion	Greenville45331	NCT06616584	Map
OH	The Ohio State University Comprehensive Cancer Center	Hilliard43026	NCT06787612	Map
OH	The Ohio State University Wexner Medical Center James Comprehensive Cancer Center	Hilliard43026	NCT03564340	Map
OH	OhioHealth Mansfield Hospital	Mansfield44903	NCT06616584	Map
OH	OhioHealth Marion General Hospital	Marion43302	NCT06616584	Map
OH	OhioHealth Pickerington Methodist Hospital	Pickerington43147	NCT06616584	Map
OH	Buckeye Dermatology - Springfield Office	Springfield45505	NCT06585410	Map
OH	ProMedica Flower Hospital	Sylvania43560	NCT06616584	Map
OH	Upper Valley Medical Center	Troy45373	NCT06616584	Map
OH	OhioHealth Westerville Medical Campus/Westerville Cancer Center	Westerville43082	NCT06616584	Map
OK	Cancer Centers of Southwest Oklahoma Research	Lawton73505	NCT06616584	Map
OK	Integris Southwest Medical Center	Oklahoma City73109	NCT06616584	Map
OK	Mercy Hospital Oklahoma City	Oklahoma City73120	NCT06616584	Map
OK	Site-116	Oklahoma City73117	NCT06384807	Map
OK	Stephenson Cancer Center	Oklahoma City73104	NCT03564340	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06585410	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06616584	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06900595	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT07195734	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT07223541	Map
OK	Oklahoma Cancer Specialists and Research Institute, LLC	Tulsa74146	NCT06246916	Map
OR	Saint Alphonsus Cancer Care Center-Baker City	Baker City97814	NCT06616584	Map
OR	Dermatology Health Specialists	Bend97702	NCT06585410	Map
OR	Clackamas Radiation Oncology Center	Clackamas97015	NCT07195734	Map
OR	Oncology Associates of Oregon PC	Eugene97401	NCT06246916	Map
OR	Legacy Mount Hood Medical Center	Gresham97030	NCT07195734	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT06616584	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT07195734	Map
OR	Saint Alphonsus Cancer Care Center-Ontario	Ontario97914	NCT06616584	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT06616584	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT07195734	Map
OR	Kaiser Foundation Hospitals	Portland97227	NCT06246916	Map
OR	Legacy Good Samaritan Hospital and Medical Center	Portland97210	NCT07195734	Map
OR	Oregon Health & Science Institute (OHSU)	Portland97239	NCT01042379	Map
OR	Oregon Health & Science University	Portland97239	NCT05317858	Map
OR	Oregon Health & Science University	Portland97239	NCT06585410	Map
OR	Oregon Health & Science University (3485 S. Bond)	Portland97239	NCT03972657	Map
OR	Oregon Health and Science University	Portland97239	NCT06246916	Map
OR	Oregon Health and Science University	Portland97239	NCT06616584	Map
OR	Providence Cancer Institute	Portland97213	NCT06171750	Map
OR	Providence Cancer Institute	Portland97213	NCT06787612	Map
OR	Providence Portland Medical Center	Portland97213	NCT06465329	Map
OR	Providence Portland Medical Center	Portland97213	NCT06616584	Map
OR	Providence Portland Medical Center	Portland97213	NCT07195734	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT06616584	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT07195734	Map
OR	University Of Nebraska Medical Center	Portland97213	NCT06465329	Map
OR	Salem Hospital	Salem97301	NCT06616584	Map
OR	Legacy Meridian Park Hospital	Tualatin97062	NCT07195734	Map
PA	UPMC-Heritage Valley Health System Beaver	Beaver15009	NCT06616584	Map
PA	UPMC Hillman Cancer Center at Butler Health System	Butler16001	NCT06616584	Map
PA	WellSpan Medical Oncology and Hematology	Chambersburg17201	NCT06616584	Map
PA	UPMC Hillman Cancer Center - Passavant - Cranberry	Cranberry Township16066	NCT06616584	Map
PA	St. Luke's University Health Network	Easton18045	NCT06246916	Map
PA	Ephrata Cancer Center	Ephrata17522	NCT06616584	Map
PA	UPMC Hillman Cancer Center Erie	Erie16505	NCT06616584	Map
PA	UPMC Cancer Center at UPMC Horizon	Farrell16121	NCT06616584	Map
PA	Adams Cancer Center	Gettysburg17325	NCT06616584	Map
PA	UPMC Cancer Centers - Arnold Palmer Pavilion	Greensburg15601	NCT06616584	Map
PA	UPMC Pinnacle Cancer Center/Community Osteopathic Campus	Harrisburg17109	NCT06616584	Map
PA	Penn State Hershey Medical Center	Hershey17033	NCT06585410	Map
PA	IRMC Cancer Center	Indiana15701	NCT06616584	Map
PA	UPMC-Johnstown/John P. Murtha Regional Cancer Center	Johnstown15901	NCT06616584	Map
PA	Sechler Family Cancer Center	Lebanon17042	NCT06616584	Map
PA	UPMC Cancer Center at UPMC McKeesport	McKeesport15132	NCT06616584	Map
PA	UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion	Mechanicsburg17050	NCT06616584	Map
PA	UPMC Hillman Cancer Center - Monroeville	Monroeville15146	NCT06616584	Map
PA	UPMC Hillman Cancer Center in Coraopolis	Moon Township15108	NCT06616584	Map
PA	UPMC Hillman Cancer Center - Part of Frick Hospital	Mount Pleasant15666	NCT06616584	Map
PA	Arnold Palmer Cancer Center Medical Oncology Norwin	N. Huntingdon15642	NCT06616584	—
PA	UPMC Cancer Center-Natrona Heights	Natrona Heights15065	NCT06616584	Map
PA	UPMC Hillman Cancer Center - New Castle	New Castle16105	NCT06616584	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT04626635	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT06246916	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT06616584	Map
PA	Hospital of the University of Pennsylvania	Philadelphia19104	NCT06585410	Map
PA	Perelman School of Medicine at the University of Pennsylvania	Philadelphia19104	NCT04590326	Map
PA	Site-108	Philadelphia19107	NCT06384807	Map
PA	Temple University Hospital	Philadelphia19140	NCT06616584	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT03972657	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT07195734	Map
PA	University of Pennsylvania (U Penn)	Philadelphia19104	NCT01042379	Map
PA	Children's Hospital of Pittsburgh of UPMC	Pittsburgh15224	NCT06900595	Map
PA	Hillman Cancer Center	Pittsburgh15232	NCT06171750	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT06616584	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT06980038	Map
PA	University of Pittsburgh Medical Center - Hillman Cancer Center	Pittsburgh15232	NCT06413680	Map
PA	University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center	Pittsburgh15232	NCT06246916	Map
PA	University of Pittsburgh Medical Center, Magee-Womens Hospital	Pittsburgh15213	NCT06787612	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT06469281	Map
PA	UPMC Hillman Cancer Center	Pittsburgh15232	NCT07223411	Map
PA	UPMC-Passavant Hospital	Pittsburgh15237	NCT06616584	Map
PA	UPMC-Saint Clair Hospital Cancer Center	Pittsburgh15243	NCT06616584	Map
PA	UPMC-Saint Margaret	Pittsburgh15215	NCT06616584	Map
PA	West Penn Hospital of Allegheny Health Network	Pittsburgh15224	NCT06787612	Map
PA	UPMC Cancer Center at UPMC Northwest	Seneca16346	NCT06616584	Map
PA	UPMC Cancer Center-Uniontown	Uniontown15401	NCT06616584	Map
PA	UPMC Cancer Center-Washington	Washington15301	NCT06616584	Map
PA	Divine Providence Hospital	Williamsport17754	NCT06616584	Map
PA	UPMC Susquehanna	Williamsport17701	NCT06616584	Map
PA	Asplundh Cancer Pavilion	Willow Grove19090	NCT07195734	Map
PA	Cancer Care Associates of York	York17403	NCT06616584	Map
RI	Brown University	Providence02912	NCT04543071	Map
RI	Lifespan Cancer Institute	Providence02903	NCT03972657	Map
RI	Lifespan Cancer Institute	Providence02903	NCT06246916	Map
RI	Lifespan Cancer Institute	Providence02903	NCT06465329	Map
RI	Rhode Island Hospital	Providence02903	NCT05317858	Map
SC	AnMed Health Cancer Center	Anderson29621	NCT06616584	Map
SC	Saint Joseph's/Candler - Bluffton Campus	Bluffton29910	NCT06616584	Map
SC	Prisma Health Cancer Institute - Spartanburg	Boiling Springs29316	NCT06900595	Map
SC	Clinical Research Center of the Carolinas	Charleston29407	NCT06585410	Map
SC	Medical University of South Carolina	Charleston29425	NCT06616584	Map
SC	Medical University of South Carolina	Charleston29425	NCT07195734	Map
SC	Prisma Health Richland Hospital	Columbia29203	NCT06900595	Map
SC	Prisma Health Cancer Institute - Easley	Easley29640	NCT06900595	Map
SC	Gibbs Cancer Center-Gaffney	Gaffney29341	NCT06616584	Map
SC	BI-LO Charities Children's Cancer Center	Greenville29605	NCT06900595	Map
SC	Prisma Health Cancer Institute - Butternut	Greenville29605	NCT06900595	Map
SC	Prisma Health Cancer Institute - Eastside	Greenville29615	NCT06900595	Map
SC	Prisma Health Cancer Institute - Faris	Greenville29605	NCT06900595	Map
SC	Gibbs Cancer Center-Pelham	Greer29651	NCT06616584	Map
SC	Prisma Health Cancer Institute - Greer	Greer29650	NCT06900595	Map
SC	South Carolina Cancer Specialists PC	Hilton Head Island29926-3827	NCT06616584	Map
SC	Prisma Health Cancer Institute - Seneca	Seneca29672	NCT06900595	Map
SC	Spartanburg Medical Center	Spartanburg29303	NCT06616584	Map
SC	SMC Center for Hematology Oncology Union	Union29379	NCT06616584	Map
SD	Rapid City Regional Hospital	Rapid City57701	NCT06616584	Map
SD	Avera Cancer Institute Sioux Falls	Sioux Falls57105	NCT06787612	Map
SD	Sanford Cancer Center	Sioux Falls57104	NCT04291105	Map
SD	Sanford Cancer Center Oncology Clinic	Sioux Falls57104	NCT06616584	Map
SD	Sanford Clinical Research	Sioux Falls57104	NCT01042379	Map
SD	Sanford USD Medical Center - Sioux Falls	Sioux Falls57117-5134	NCT06616584	Map
SD	Prairie Lakes Healthcare System	Watertown57201	NCT06465329	Map
TN	Tennessee Oncology - Chattanooga	Chattanooga37404	NCT06246916	Map
TN	Baptist Memorial Hospital and Cancer Center-Collierville	Collierville38017	NCT06616584	Map
TN	University of Tennessee Medical Center	Knoxville37920	NCT06246916	Map
TN	University of Tennessee Medical Center	Knoxville37920	NCT06465329	Map
TN	Baptist Memorial Hospital and Cancer Center-Memphis	Memphis38120	NCT06616584	Map
TN	Saint Jude Children's Research Hospital	Memphis38105	NCT06900595	Map
TN	Sarah Cannon Research Institute	Nashville37203	NCT03564340	Map
TN	Sarah Cannon Research Institute - 25th Ave	Nashville37203	NCT04626635	Map
TN	Sarah Cannon Research Institute (SCRI) Oncology Partners	Nashville37203	NCT06246916	Map
TN	Sarah Cannon Research Institute (SCRI) Oncology Partners	Nashville37203	NCT06465329	Map
TN	Site-107	Nashville37203	NCT06384807	Map
TN	Tennessee Oncology	Nashville37203	NCT06246916	Map
TN	Tennessee Oncology	Nashville37203	NCT06465329	Map
TN	Vanderbilt Ingram Cancer Center	Nashville37232	NCT04626635	Map
TN	Vanderbilt University/Ingram Cancer Center	Nashville37232	NCT05501665	Map
TN	Vanderbilt University/Ingram Cancer Center	Nashville37232	NCT07195734	Map
TN	Vanderbilt-Ingram Cancer Center	Nashville37232	NCT06769698	Map
TN	Vanderbilt-Ingram Cancer Center	Nashville37232	NCT07188896	Map
TX	The Don and Sybil Harrington Cancer Center	Amarillo79106	NCT06616584	Map
TX	Dell Children's Medical Center of Central Texas	Austin78723	NCT06900595	Map
TX	NEXT Austin	Austin78758	NCT06090266	Map
TX	Texas Oncology - Austin Central	Austin78745	NCT06463665	Map
TX	Texas Oncology - Austin Central, Central Austin Cancer Center	Austin78731	NCT06246916	Map
TX	Texas Oncology - Austin Midtown, Midtown Medical Center I	Austin78705	NCT06246916	Map
TX	The University of Texas at Austin Dell Medical School Ascension Medical Group	Austin78701	NCT06585410	Map
TX	World Research Link	Baytown77521	NCT06463665	Map
TX	Texas Oncology - Bedford	Bedford76022	NCT06246916	Map
TX	Reveal Research Institute	Dallas75235	NCT06585410	Map
TX	Site-104	Dallas75231	NCT06384807	Map
TX	Texas Oncology	Dallas75246	NCT06246916	Map
TX	Texas Oncology - Medical City	Dallas75230	NCT06246916	Map
TX	University of Texas Southwestern	Dallas75390	NCT05137054	Map
TX	UT Southwestern Medical Center	Dallas75390	NCT06787612	Map
TX	Center For Disease And Blood Disorder	Fort Worth76104	NCT06246916	Map
TX	Texas Oncology - Fort Worth	Fort Worth76104	NCT06246916	Map
TX	Texas Oncology - Grapevine	Grapevine76051	NCT06246916	Map
TX	Texas Oncology - Harlingen, Medical Arts Pavillion	Harlingen78550	NCT06246916	Map
TX	Md Anderson Cancer Center	Houston77030	NCT06651593	Map
TX	MD Anderson Cancer Center	Houston77030	NCT04626635	Map
TX	MD Anderson Cancer Center	Houston77030	NCT03972657	Map
TX	MD Anderson Cancer Center	Houston77030	NCT05142189	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06412198	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06413680	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06444880	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06448026	Map
TX	The University of Texas M. D. Anderson Cancer Center	Houston77030	NCT06826768	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT06246916	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT06585410	Map
TX	NEXT Dallas	Irving75039	NCT06090266	Map
TX	Epiphany Dermatology	Lewisville75056	NCT06585410	Map
TX	Texas Oncology - Longview	Longview75601	NCT06246916	Map
TX	Joe Arrington Cancer Research & Treatment Center	Lubbock79410	NCT06246916	Map
TX	Joe Arrington Cancer Research & Treatment Center	Lubbock79410	NCT06769698	Map
TX	Texas Oncology - McAllen	McAllen78503	NCT06246916	Map
TX	Texas Oncology-Palestine Cancer Center	Palestine75801	NCT06246916	Map
TX	Children's Hospital of San Antonio	San Antonio78207	NCT06900595	Map
TX	Next Oncology	San Antonio78229	NCT06413680	Map
TX	NEXT Oncology	San Antonio78229	NCT06090266	Map
TX	Texas Dermatology and Laser Specialists	San Antonio78218	NCT06585410	Map
TX	The Start Center for Cancer Care	San Antonio78229	NCT06413680	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT06900595	Map
TX	Texas Oncology-Tyler, Northeast Texas Cancer Institute	Tyler75702	NCT06246916	Map
TX	Center for Clinical Studies at Webster Clear Lake	Webster77598	NCT06585410	Map
TX	Texas Oncology - Weslaco, Knapp Medical Plaza	Weslaco78596	NCT06246916	Map
UT	Huntsman Cancer Institute, University of Utah	Salt Lake City84112	NCT01042379	Map
UT	Huntsman Cancer Institute/University of Utah	Salt Lake City84112	NCT06616584	Map
UT	LDS Hospital	Salt Lake City84143	NCT06469281	Map
UT	University of Utah Hospital	Salt Lake City84132	NCT06585410	Map
UT	University of Utah Huntsman Cancer Institute	Salt Lake City84112	NCT06246916	Map
UT	Site-106	West Valley City84119	NCT06384807	Map
VT	Dartmouth Cancer Center - North	Saint Johnsbury05819	NCT06616584	Map
VT	White River Junction Veteran Administration Medical Center	White River Junction05009	NCT06616584	Map
VA	BRCC/Oncology & Hematology Associates of SW Virginia	Blacksburg24060	NCT06465329	Map
VA	Emily Couric Clinical Cancer Center	Charlottesville22908	NCT03972657	Map
VA	University of Virginia	Charlottesville22908	NCT06246916	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT06616584	Map
VA	UVA Comprehensive Cancer Center	Charlottesville22908	NCT06449313	Map
VA	Inova Schar Cancer Institute	Fairfax22031	NCT06246916	Map
VA	Inova Schar Cancer Institute	Fairfax22031	NCT06769698	Map
VA	NEXT Virginia	Fairfax22031	NCT05142189	Map
VA	NEXT Virginia	Fairfax22031	NCT06090266	Map
VA	Site-102	Fairfax22031	NCT06384807	Map
VA	Virginia Cancer Specialists, PC	Fairfax22031	NCT06246916	Map
VA	Centra Alan B Pearson Regional Cancer Center	Lynchburg24501	NCT06616584	Map
VA	Kaiser Permanente Tysons Corner Medical Center	McLean22102	NCT06616584	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT06246916	Map
VA	Johnston Willis Hospital	Richmond23235	NCT05317858	Map
VA	VCU Massey Cancer Center at Stony Point	Richmond23235	NCT06616584	Map
VA	VCU Massey Cancer Center at Stony Point	Richmond23235	NCT06900595	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06616584	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06900595	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06980038	Map
VA	Virginia Cancer Institute	Richmond23229	NCT06616584	Map
VA	Virginia Commonwealth University	Richmond23219	NCT03564340	Map
VA	Virginia Commonwealth University Massey Cancer Center	Richmond23298	NCT06246916	Map
VA	Oncology & Hematology Associates of Southwest Virginia, Inc.	Roanoke24014	NCT06246916	Map
VA	VCU Community Memorial Health Center	South Hill23970	NCT06616584	Map
VA	Kaiser Permanente-Caton Hill Medical Center	Woodbridge22192	NCT06616584	Map
WA	Swedish Cancer Institute - Edmonds Campus	Edmonds98026	NCT06246916	Map
WA	Swedish Cancer Institute - Issaquah Campus	Issaquah98029	NCT06246916	Map
WA	Kadlec Clinic Hematology and Oncology	Kennewick99336	NCT06246916	Map
WA	Seattle Cancer Care Alliance at South Lake Union - G3630	Seattle98109	NCT04590326	Map
WA	Swedish Cancer Institute	Seattle98104	NCT06246916	Map
WA	Swedish Cancer Institute	Seattle98104	NCT06787612	Map
WA	University of Washington/Fred Hutchinson Cancer Center	Seattle98109	NCT04626635	Map
WA	VA Puget Sound Health Care System	Seattle98108	NCT05137054	Map
WA	Legacy Cancer Institute Medical Oncology and Day Treatment	Vancouver98684	NCT07195734	Map
WA	Legacy Salmon Creek Hospital	Vancouver98686	NCT07195734	Map
WV	United Hospital Center	Bridgeport26330	NCT06616584	Map
WV	Edwards Comprehensive Cancer Center	Huntington25701	NCT06616584	Map
WV	WVUH-Berkely Medical Center	Martinsburg25401	NCT06616584	Map
WV	West Virginia University	Morgantown26506	NCT06246916	Map
WV	West Virginia University Healthcare	Morgantown26506	NCT06616584	Map
WV	Camden Clark Medical Center	Parkersburg26101	NCT06616584	Map
WV	Wheeling Hospital/Schiffler Cancer Center	Wheeling26003	NCT06616584	Map
WI	Duluth Clinic Ashland	Ashland54806	NCT06616584	Map
WI	Aurora Cancer Care-Southern Lakes VLCC	Burlington53105	NCT06616584	Map
WI	Aurora Saint Luke's South Shore	Cudahy53110	NCT06616584	Map
WI	Aurora Health Care Germantown Health Center	Germantown53022	NCT06616584	Map
WI	Aurora Cancer Care-Grafton	Grafton53024	NCT06616584	Map
WI	Aurora BayCare Medical Center	Green Bay54311	NCT06616584	Map
WI	Saint Vincent Hospital Cancer Center at Saint Mary's	Green Bay54303	NCT06616584	Map
WI	Saint Vincent Hospital Cancer Center Green Bay	Green Bay54301	NCT06616584	Map
WI	Aurora Cancer Care-Kenosha South	Kenosha53142	NCT06616584	Map
WI	Gundersen Lutheran Medical Center	La Crosse54601	NCT06616584	Map
WI	University of Wisconsin	Madison53792	NCT06787612	Map
WI	University of Wisconsin Carbone Cancer Center	Madison53792	NCT04989946	Map
WI	University of Wisconsin Carbone Cancer Center	Madison53792	NCT06246916	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT06616584	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT07195734	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT06616584	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT07195734	Map
WI	Aurora Bay Area Medical Group-Marinette	Marinette54143	NCT06616584	Map
WI	Froedtert Menomonee Falls Hospital	Menomonee Falls53051	NCT07195734	Map
WI	Aurora Cancer Care-Milwaukee	Milwaukee53209	NCT06616584	Map
WI	Aurora Saint Luke's Medical Center	Milwaukee53215	NCT06616584	Map
WI	Aurora Sinai Medical Center	Milwaukee53233	NCT06616584	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT04626635	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06787612	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT07195734	Map
WI	Medical College of Wisconsin, Wisconsin Diagnostic Labratories	Milwaukee53226	NCT04543071	Map
WI	Froedtert and MCW Moorland Reserve Health Center	New Berlin53151	NCT07195734	Map
WI	Drexel Town Square Health Center	Oak Creek53154	NCT07195734	Map
WI	Saint Vincent Hospital Cancer Center at Oconto Falls	Oconto Falls54154	NCT06616584	Map
WI	Vince Lombardi Cancer Clinic - Oshkosh	Oshkosh54904	NCT06616584	Map
WI	Aurora Cancer Care-Racine	Racine53406	NCT06616584	Map
WI	Saint Vincent Hospital Cancer Center at Sheboygan	Sheboygan53081	NCT06616584	Map
WI	Sheboygan Physicians Group	Sheboygan53081	NCT06616584	Map
WI	Vince Lombardi Cancer Clinic-Sheboygan	Sheboygan53081	NCT06616584	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT06616584	Map
WI	Saint Vincent Hospital Cancer Center at Sturgeon Bay	Sturgeon Bay54235-1495	NCT06616584	Map
WI	Aurora Medical Center in Summit	Summit53066	NCT06616584	—
WI	Vince Lombardi Cancer Clinic-Two Rivers	Two Rivers54241	NCT06616584	Map
WI	Aurora Cancer Care-Milwaukee West	Wauwatosa53226	NCT06616584	Map
WI	Aurora West Allis Medical Center	West Allis53227	NCT06616584	Map
WI	Froedtert West Bend Hospital/Kraemer Cancer Center	West Bend53095	NCT07195734	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT06616584	Map

Cemiplimab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	suspended	not yet recruiting	unknown	no longer available	approved for marketing	Total
P1	15	3	1	8	6	1		2	1			37
P1/P2	14	8		3	7	2		1	1			36
P2	42	20	1	8	3	5	2	18	2			101
P2/P3	1	2										3
P3	5	3		2			1					11
N/A	5			2				1		1	1	10

Recruiting Cemiplimab clinical trials (106)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07050186	Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma	P2	Metastatic NUT Carcinoma	15	Aug 2025
NCT07365839	CLeARCemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma	P1	Hepatocellular Carcinoma	20	Jul 2026
NCT05137054	A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments	P1	Multiple Myeloma	317	Aug 2022
NCT07567469	A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma	P1/P2	High-Grade Glioma (HGG)	120	Aug 2026
NCT06246916	A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)	P3	Melanoma	560	Sep 2024
NCT07195734	Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer	P2	Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	180	Apr 2026
NCT06449313	NEO-SURGNeoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement	P2	Non-small Cell Lung Cancer Stage III	21	Aug 2026
NCT07001618	IMMUNOLIFE2Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer	P2	NSCLC (Advanced Non-small Cell Lung Cancer)	162	Nov 2025
NCT07470489	Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer	P2	Anaplastic Thyroid Cancer	12	Sep 2026
NCT07360743	META-1Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels	P2	Non Small Cell Lung Cancer (Squamous or Non Squamous)	275	Apr 2026
NCT06508463	Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma	P1	Peripheral T Cell Lymphoma	21	Jan 2024
NCT03017820	A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	P1	B-Cell Non-Hodgkin Lymphoma	99	Apr 2017
NCT06656598	SPORADICAdjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer	P2	Stage III NSCLC	152	Nov 2025
NCT06623656	Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC	P2	Carcinoma, Non-Small-Cell Lung	112	Feb 2025
NCT01042379	I-SPYI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	P2	Breast Neoplasms	5,000	Mar 2010
NCT06917573	PALACEPALACE: Cemiplimab Trial According to ctDNA Levels	P2	Non Small Cell Lung Cancer Metastatic	63	Jul 2025
NCT05142189	LuCa-MERIT-1Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer	P1	Non-Small Cell Lung Cancer	320	Jun 2022
NCT07223411	Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma	—	Locally Advanced Melanoma	20	Nov 2025
NCT04428671	Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer	P1	Metastatic Skin Squamous Cell Carcinoma	20	May 2020
NCT07223541	LAG-BOOSTCemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma	P2	Clear Cell Renal Cell Carcinoma	72	Jan 2026
NCT07346196	A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck	P2	Squamous Cell Carcinoma	90	Feb 2027
NCT07387198	NeoMatryxNeoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab	P2	Merkel Cell Carcinoma, Stage I	135	Jun 2026
NCT07061379	PROMOTINGPatient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen	—	PROMs	144	Jul 2025
NCT07404332	5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors	P1	Solid Tumor	35	Feb 2026
NCT06769698	A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	P2	Head and Neck Squamous Cell Carcinoma (HNSCC)	120	Apr 2026
NCT07281417	REGN2810Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma	P2	Sinonasal Squamous Cell Carcinoma	108	Nov 2026
NCT06418724	NEOPECSNeoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma	P2	Locally Advanced Cutaneous Squamous Cell Carcinoma	27	Jul 2026
NCT07418931	CECYDEA Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer	P2	Advanced Squamous Non-Small Cell Lung Cancer	108	May 2026
NCT07188896	RCCA Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)	P2	Advanced Renal Cell Carcinoma (aRCC)	120	Apr 2026
NCT06121180	Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma	P2	Metastatic Uveal Melanoma	32	Nov 2024
NCT07020065	Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%	P2	Metastatic NSCLC - Non-Small Cell Lung Cancer	156	Apr 2026
NCT06651593	Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors	P2	Solid Tumors	40	Jul 2025
NCT07281768	Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer	P2	Colorectal Cancer	66	Jul 2026
NCT07274384	HYPERBOLICHyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial	P2	NSCLC (Non-small Cell Lung Cancer)	74	Jan 2026
NCT06205836	Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer	P2	Colorectal Cancer	44	Jun 2024
NCT06469281	MUC16A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers	P1	Epithelial Ovarian Cancer	90	Aug 2024
NCT07511036	PROSECCOPROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma	P2	Melanoma	20	Sep 2026
NCT06585410	Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma	P3	Cutaneous Squamous Cell Carcinoma (CSCC)	369	Jan 2025
NCT06465329	NSCLCA Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)	P2	Non-Small Cell Lung Cancer	120	Nov 2024
NCT06743581	Dupi-CemiPhase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer	N/A	Non-Small Cell Lung Cancer	24	Feb 2025
NCT06413680	BrILlianceA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body	P1/P2	Melanoma	240	Sep 2024
NCT07527325	TNTFianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma	P2	Melanoma (Skin)	35	Jul 2026
NCT06219317	ICARSImmunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC	P2	NSCLC Stage IV	136	Jan 2025
NCT06790602	SWITCHCemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma	P2	Pancreatic Ductal Adenocarcinoma (mPDAC)	43	May 2026
NCT07179315	A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment	P2	Head and Neck Cancer	68	Dec 2026
NCT07224022	NAChoCemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer	P2	Colon Cancer	24	Jul 2026
NCT07264673	CemitedA Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.	P2	NSCLC	160	Apr 2025
NCT06848088	A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment	P2	Melanoma	48	Apr 2025
NCT07234058	LAG-MAPSTrial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma	P2	Pleural Mesotheliomas	126	Feb 2026
NCT06981325	CEMI-firstEvaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients	P2	Basal Cell Carcinoma (BCC)	34	Aug 2025
NCT06463665	VIRO-25Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer	P2	Advanced Non-squamous Non-small-cell Lung Cancer	142	Sep 2024
NCT06900595	REGN2810Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer	P2	Locally Advanced Adrenal Cortical Carcinoma	48	Feb 2026
NCT07058012	EMPIREA Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)	P2	Colo-rectal Cancer	79	Apr 2026
NCT06826768	A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC	P1	Prostate Cancer	60	Jul 2025
NCT06931717	ARCHA Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy	P3	Non-Small Cell Lung Cancer	390	Jan 2026
NCT06412198	A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations	P1/P2	Metastatic Colorectal Cancer	31	Aug 2024
NCT07433673	GAP CemiGemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)	P2	Colon and Rectal Cancer	20	Aug 2026
NCT07101822	BRAVA PENILEA PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER	P2	Penile Cancer	42	Dec 2025
NCT07101848	BRAVA VULVARA PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER	P2	Vulvar Cancers	42	Nov 2025
NCT07251413	CEMIQUIDCemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma	P1/P2	Cutaneous Basal Cell Carcinoma	18	Oct 2025
NCT06571708	NeoSTOP-ITGemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)	P2	Bladder Cancer	36	Aug 2025
NCT06616584	Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)	P2/P3	Recurrent Lung Non-Small Cell Carcinoma	378	May 2025
NCT04989946	Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer	P1/P2	Prostate Cancer	60	Dec 2021
NCT06787612	Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer	P2	Ovarian Cancer	220	May 2025
NCT05363319	CEMI-LUNGAn Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe	—	Non-small Cell Lung Cancer	500	Oct 2022
NCT06902376	NEO-COMBATXLXL092 and Cemiplimab in BRAF WT Thyroid Cancer	P1	Anaplastic Thyroid Cancer	12	Jun 2025
NCT04543071	Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma	P2	Pancreatic Cancer	10	Nov 2020
NCT07085572	INTERVALCemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer	P2	Adrenal Cortical Carcinoma	31	Sep 2025
NCT06444880	Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies	P2	SMARCB1-Deficient Malignancies	40	Oct 2024
NCT06943664	Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer	P2	Lung Non-Small Cell Carcinoma	27	May 2026
NCT06923761	EMITT-1EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)	P1/P2	Advanced Solid Malignancy	300	May 2023
NCT07414992	A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer	P2	Bladder Urothelial Carcinoma	44	May 2026
NCT04975152	Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma	P1	Merkel Cell Carcinoma	36	Oct 2021
NCT06699602	A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma	P2	Renal Cell Carcinoma	10	Feb 2025
NCT06384807	A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors	P1/P2	Solid Tumor	500	Apr 2024
NCT06887088	ENCEFALOEncorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases	P2	Melanoma BRAF V600E/K Mutated	33	May 2025
NCT06731270	Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy	P2	Advanced Lung Non-Small Cell Carcinoma	20	Apr 2025
NCT06908304	A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC	P3	Carcinoma, Non-Small -Cell Lung	300	Dec 2025
NCT06528769	ATRAStudy of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma	P2	Leiomyosarcoma	16	Sep 2025
NCT04988074	MINIMATrial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca	P2	HPV-Related Squamous Cell Carcinoma	32	Dec 2021
NCT07450183	Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1	P2	Lung Cancer (NSCLC)	33	Jun 2026
NCT05317858	LIMITLESSBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets	P3	Brain Tumor	30	Aug 2022
NCT04590326	A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab	P1/P2	Ovarian Cancer	612	Dec 2020
NCT06980038	REGN2810Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer	P2	Head and Neck Squamous Cell Carcinoma	44	May 2026
NCT03972657	A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors	P1/P2	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	345	Aug 2019
NCT07147231	CX-5461Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer	P1/P2	Metastatic Colorectal Adenocarcinoma	86	Dec 2026
NCT06594991	A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma	P2	Advanced Melanoma	88	Sep 2024
NCT06865339	TRIPLThoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer	P2	NSCLC	76	Aug 2025
NCT07064330	NGF-GRACENext-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.	—	Cutaneous Squamous Cell Carcinoma (CSCC)	30	Jul 2025
NCT06171750	ANCHORPhase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors	P1	Advanced Solid Tumor	97	Jan 2024
NCT06448026	OCSCCCemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).	P2	Locally Recurrent Oral Cavity Squamous Cell Carcinoma	17	Nov 2024
NCT03564340	Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers	P1/P2	Recurrent Ovarian Cancer	890	May 2018
NCT06918132	N-PLANCCemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer	P2	Lung Non-Small Cell Carcinoma	60	Apr 2025
NCT06088771	Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC	P1/P2	Non-Small Cell Lung Cancer	21	Mar 2024
NCT04626635	COMBINE-EGFR-1A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers	P1/P2	Advanced Solid Tumors	933	Dec 2020
NCT06302426	Trial of INI-4001 in Patients With Advanced Solid Tumours	P1	Advanced Solid Tumor	50	Jul 2024
NCT07422363	REGN2810Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma	P1	Recurrent Glioblastoma, IDH-Wildtype	30	Jun 2026
NCT06090266	A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents	P1/P2	Cancer	168	Oct 2023
NCT05501665	Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer	P1/P2	Lung Non-Small Cell Carcinoma	25	May 2023
NCT06860815	Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer	P2	Anatomic Stage IV Breast Cancer AJCC v8	11	Jan 2026
NCT05259709	A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab	P1	Advanced Solid Tumor	50	Feb 2023
NCT06532149	EROSERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer	—	NSCLC Stage IV	80	Aug 2024
NCT06022029	ON-5001A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.	P1	Triple Negative Breast Cancer	168	Oct 2023
NCT04722523	A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer	P1	Head and Neck Cancer	40	Jan 2021
NCT04291105	Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients	P2	Melanoma	87	Apr 2020
NCT05376553	Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck	P1	Locally Advanced Head and Neck Squamous Cell Carcinoma	24	Jul 2022

Cemiplimab clinical trials by indication

Cutaneous Squamous Cell Carcinoma (13)

NCT	Acronym	Phase	Status	Title
NCT06384820	CSCC	P2	withdrawn	Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
NCT05878288	DISCERN	P2	active not recruiting	Deep sequencIng in Cutaneous Squamous CEll caRciNomas
NCT05729139	—	P1	withdrawn	Cemiplimab/Peg-Interferon-α in Advanced CSCC
NCT03969004	—	P3	active not recruiting	Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
NCT05574101	—	P2	active not recruiting	A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
NCT04632433	—	P2	active not recruiting	Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma
NCT03889912	—	P1	completed	Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
NCT04154943	—	P2	completed	Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
+ 5 more, see All trials below.

Melanoma (8)

NCT	Acronym	Phase	Status	Title
NCT06246916	—	P3	recruiting	A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT05352672	—	P3	active not recruiting	Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT06190951	—	P2	active not recruiting	A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT07511036	PROSECCO	P2	not yet recruiting	PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
NCT05608291	—	P3	active not recruiting	A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT06413680	BrILliance	P1/P2	recruiting	A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
NCT06848088	—	P2	enrolling by invitation	A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
NCT04291105	—	P2	recruiting	Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Non-Small Cell Lung Cancer (6)

NCT	Acronym	Phase	Status	Title
NCT05142189	LuCa-MERIT-1	P1	recruiting	Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT06465329	NSCLC	P2	recruiting	A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
NCT06743581	Dupi-Cemi	N/A	not yet recruiting	Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
NCT06931717	ARCH	P3	recruiting	A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
NCT06088771	—	P1/P2	recruiting	Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
NCT05882734	M1774	P1/P2	active not recruiting	Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Prostate Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT06826768	—	P1	recruiting	A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
NCT04989946	—	P1/P2	recruiting	Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
NCT04382898	PRO-MERIT	P1/P2	terminated	PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
NCT03367819	—	P1/P2	terminated	Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Carcinoma, Non-Small-Cell Lung (4)

NCT	Acronym	Phase	Status	Title
NCT06623656	—	P2	recruiting	Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
NCT05208944	—	P2	active not recruiting	THIO Sequenced With Cemiplimab in Advanced NSCLC
NCT05401786	RAD-IO	P2	active not recruiting	Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC
NCT03580694	NSCLC	P1	terminated	Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Head and Neck Squamous Cell Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT06855212	—	P2	active not recruiting	Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
NCT06980038	REGN2810	P2	recruiting	Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
NCT04831450	HNSCC	P2	withdrawn	Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

Lung Non-Small Cell Carcinoma (3)

NCT	Acronym	Phase	Status	Title
NCT06943664	—	P2	not yet recruiting	Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
NCT06918132	N-PLANC	P2	recruiting	Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
NCT05501665	—	P1/P2	recruiting	Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Advanced Solid Tumor (3)

NCT	Acronym	Phase	Status	Title
NCT06171750	ANCHOR	P1	recruiting	Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
NCT06302426	—	P1	recruiting	Trial of INI-4001 in Patients With Advanced Solid Tumours
NCT05259709	—	P1	recruiting	A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

Non-small Cell Lung Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT05800015	—	P2/P3	active not recruiting	A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
NCT03916627	—	P2	active not recruiting	Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
NCT05363319	CEMI-LUNG	N/A	recruiting	An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Solid Tumor, Adult (3)

NCT	Acronym	Phase	Status	Title
NCT05864144	—	P1/P2	active not recruiting	A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05662397	—	P1/P2	active not recruiting	A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
NCT05054348	—	P1	completed	First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Glioblastoma (3)

NCT	Acronym	Phase	Status	Title
NCT03491683	EP	P1/P2	active not recruiting	INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
NCT04826393	—	P1	completed	ASP8374 + Cemiplimab in Recurrent Glioma
NCT04006119	—	P2	terminated	Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Squamous Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT07346196	—	P2	not yet recruiting	A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
NCT05535023	—	P2	withdrawn	Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

Head and Neck Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07179315	—	P2	not yet recruiting	A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment
NCT04722523	—	P1	recruiting	A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Anaplastic Thyroid Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07470489	—	P2	not yet recruiting	Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
NCT06902376	NEO-COMBATXL	P1	recruiting	XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Colorectal Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07281768	—	P2	not yet recruiting	Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
NCT06205836	—	P2	recruiting	Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Colon Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT07224022	NACho	P2	not yet recruiting	Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer
NCT05961709	—	P2	active not recruiting	The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Solid Tumor (2)

NCT	Acronym	Phase	Status	Title
NCT07404332	—	P1	recruiting	5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
NCT06384807	—	P1/P2	recruiting	A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

NSCLC (2)

NCT	Acronym	Phase	Status	Title
NCT07264673	Cemited	P2	recruiting	A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.
NCT06865339	TRIPL	P2	recruiting	Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Cutaneous Squamous Cell Carcinoma (CSCC) (2)

NCT	Acronym	Phase	Status	Title
NCT06585410	—	P3	recruiting	Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT07064330	NGF-GRACE	N/A	recruiting	Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

Ovarian Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06787612	—	P2	recruiting	Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
NCT04590326	—	P1/P2	recruiting	A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Renal Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT06699602	—	P2	recruiting	A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
NCT03294083	—	P1/P2	active not recruiting	A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

NSCLC Stage IV (2)

NCT	Acronym	Phase	Status	Title
NCT06219317	ICARS	P2	recruiting	Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
NCT06532149	EROS	N/A	recruiting	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Non-small Cell Lung Cancer (NSCLC) (2)

NCT	Acronym	Phase	Status	Title
NCT06162572	NSCLC	P1/P2	active not recruiting	Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT05553834	—	P2	active not recruiting	PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06090266	—	P1/P2	recruiting	A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT05094804	—	P1/P2	unknown	A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Triple Negative Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06022029	ON-5001	P1	recruiting	A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06052852	—	P1	terminated	Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Advanced Non-Small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT05785767	NSCLC	P2/P3	active not recruiting	A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05557591	—	P2	active not recruiting	A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Plasma Cell Myeloma (2)

NCT	Acronym	Phase	Status	Title
NCT05669989	—	P2	active not recruiting	International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
NCT03194867	RRMM	P1/P2	completed	Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Merkel Cell Carcinoma (2)

NCT	Acronym	Phase	Status	Title
NCT04975152	—	P1	recruiting	Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
NCT04916002	—	P2	terminated	A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Metastatic Colorectal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07147231	CX-5461	P1/P2	recruiting	Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

Sinonasal Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07281417	REGN2810	P2	recruiting	Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

High-Grade Glioma (HGG) (1)

NCT	Acronym	Phase	Status	Title
NCT07567469	—	P1/P2	not yet recruiting	A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Colon and Rectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07433673	GAP Cemi	P2	recruiting	Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Locally Advanced Cutaneous Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06418724	NEOPECS	P2	not yet recruiting	Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

Hepatocellular Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07365839	CLeAR	P1	not yet recruiting	Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

Merkel Cell Carcinoma, Stage I (1)

NCT	Acronym	Phase	Status	Title
NCT07387198	NeoMatryx	P2	not yet recruiting	Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

Recurrent Glioblastoma, IDH-Wildtype (1)

NCT	Acronym	Phase	Status	Title
NCT07422363	REGN2810	P1	not yet recruiting	Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Lung Cancer (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT07450183	—	P2	not yet recruiting	Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

Advanced Squamous Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07418931	CECYDE	P2	not yet recruiting	A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer

Bladder Urothelial Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07414992	—	P2	not yet recruiting	A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

Non-small Cell Lung Cancer Stage III (1)

NCT	Acronym	Phase	Status	Title
NCT06449313	NEO-SURG	P2	recruiting	Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Melanoma (Skin) (1)

NCT	Acronym	Phase	Status	Title
NCT07527325	TNT	P2	not yet recruiting	Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

Non Small Cell Lung Cancer (Squamous or Non Squamous) (1)

NCT	Acronym	Phase	Status	Title
NCT07360743	META-1	P2	not yet recruiting	Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

Pancreatic Ductal Adenocarcinoma (mPDAC) (1)

NCT	Acronym	Phase	Status	Title
NCT06790602	SWITCH	P2	recruiting	Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Advanced Renal Cell Carcinoma (aRCC) (1)

NCT	Acronym	Phase	Status	Title
NCT07188896	RCC	P2	recruiting	A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT07195734	—	P2	recruiting	Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC) (1)

NCT	Acronym	Phase	Status	Title
NCT06769698	—	P2	recruiting	A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Metastatic NSCLC - Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07020065	—	P2	recruiting	Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Anatomic Stage IV Breast Cancer AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT06860815	—	P2	recruiting	Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

Pleural Mesotheliomas (1)

NCT	Acronym	Phase	Status	Title
NCT07234058	LAG-MAPS	P2	not yet recruiting	Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

Locally Advanced Adrenal Cortical Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06900595	REGN2810	P2	recruiting	Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Clear Cell Renal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07223541	LAG-BOOST	P2	recruiting	Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

NSCLC (Non-small Cell Lung Cancer) (1)

NCT	Acronym	Phase	Status	Title
NCT07274384	HYPERBOLIC	P2	not yet recruiting	Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial

Penile Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07101822	BRAVA PENILE	P2	not yet recruiting	A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER

Carcinoma, Non-Small -Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT06908304	—	P3	recruiting	A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Locally Advanced Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT07223411	—	N/A	recruiting	Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

NSCLC (Advanced Non-small Cell Lung Cancer) (1)

NCT	Acronym	Phase	Status	Title
NCT07001618	IMMUNOLIFE2	P2	recruiting	Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Stage III NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT06656598	SPORADIC	P2	recruiting	Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

Vulvar Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT07101848	BRAVA VULVAR	P2	not yet recruiting	A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER

Cutaneous Basal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07251413	CEMIQUID	P1/P2	recruiting	Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma

Adrenal Cortical Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07085572	INTERVAL	P2	recruiting	Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer

Leiomyosarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT06528769	ATRA	P2	recruiting	Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Metastatic NUT Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07050186	—	P2	recruiting	Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06571708	NeoSTOP-IT	P2	recruiting	Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Basal Cell Carcinoma (BCC) (1)

NCT	Acronym	Phase	Status	Title
NCT06981325	CEMI-first	P2	recruiting	Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

Colo-rectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07058012	EMPIRE	P2	recruiting	A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

Non Small Cell Lung Cancer Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT06917573	PALACE	P2	recruiting	PALACE: Cemiplimab Trial According to ctDNA Levels

PROMs (1)

NCT	Acronym	Phase	Status	Title
NCT07061379	PROMOTING	N/A	recruiting	Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen

Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT06651593	—	P2	recruiting	Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

Melanoma BRAF V600E/K Mutated (1)

NCT	Acronym	Phase	Status	Title
NCT06887088	ENCEFALO	P2	recruiting	Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Recurrent Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06616584	—	P2/P3	recruiting	Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Metastatic Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05840770	—	P2	withdrawn	Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Advanced Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06731270	—	P2	recruiting	Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Non Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06385262	TOP 2301	P2	suspended	TOP 2301: Neoadjuvant Chemo for NSCLC

Eyelid Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06568172	REGN2810	P3	suspended	Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Mycosis Fungoides (1)

NCT	Acronym	Phase	Status	Title
NCT05538988	BIOSELECT	P1/P2	withdrawn	BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma

Locally Recurrent Oral Cavity Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06448026	OCSCC	P2	recruiting	Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

Metastatic Uveal Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT06121180	—	P2	recruiting	Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

SMARCB1-Deficient Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT06444880	—	P2	recruiting	Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Advanced Non-squamous Non-small-cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06463665	VIRO-25	P2	recruiting	Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Advanced Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT06594991	—	P2	recruiting	A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06412198	—	P1/P2	recruiting	A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Epithelial Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06469281	MUC16	P1	recruiting	A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Resectable Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06161441	—	P2	active not recruiting	A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Peripheral T Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06508463	—	P1	recruiting	Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Hepatitis B Virus (1)

NCT	Acronym	Phase	Status	Title
NCT04046107	—	P1/P2	withdrawn	Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05704634	—	P1	active not recruiting	A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05967884	—	P2	unknown	PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Locally Advanced Basal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05929664	—	P2	suspended	Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Advanced Dedifferentiated Liposarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT05694871	—	P2	active not recruiting	Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Advanced Solid Malignancy (1)

NCT	Acronym	Phase	Status	Title
NCT06923761	EMITT-1	P1/P2	recruiting	EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT05137054	—	P1	recruiting	A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Brain Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT05317858	LIMITLESS	P3	recruiting	Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Locally Advanced Head and Neck Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05376553	—	P1	enrolling by invitation	Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Oncology (1)

NCT	Acronym	Phase	Status	Title
NCT05259696	GLIMMER-01	P1/P2	completed	Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Metastatic Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04706715	—	P1/P2	active not recruiting	LAG3 PET Imaging in Advanced Solid Tumors

Cancer/Squamous Cell Carcinoma of Skin (1)

NCT	Acronym	Phase	Status	Title
NCT05302297	TOSCA	N/A	completed	Comparative Efficacy of Cemiplimab to Historical Standard of Care in France

Secondary Angiosarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT04873375	—	P2	completed	Cemiplimab for Secondary Angiosarcomas

HPV-Related Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04988074	MINIMA	P2	recruiting	Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (1)

NCT	Acronym	Phase	Status	Title
NCT04862650	—	P2	active not recruiting	Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Advanced NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT04982224	MET	P1	terminated	Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Hormone Receptor-positive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05064085	—	P1	completed	Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Malignant Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT04913220	—	P1/P2	terminated	A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Cervical Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04646005	HPV	P2	completed	Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Natural Killer/T-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04763616	ICING	P2	completed	Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

Melanoma Stage III (1)

NCT	Acronym	Phase	Status	Title
NCT04526899	—	P2	completed	A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

Basal Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04679480	—	P2	active not recruiting	Anti-PD1-antibody and Pulsed HHI for Advanced BCC

Advanced Malignant Solid Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04729725	—	P1	terminated	SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Advanced Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT04626635	COMBINE-EGFR-1	P1/P2	recruiting	A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Recurrent Head and Neck Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04305795	—	P1/P2	active not recruiting	An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Metastatic Pancreatic Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04177810	—	P2	completed	Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04373083	—	P2	withdrawn	Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Pancreatic Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04543071	—	P2	recruiting	Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Squamous Cell Carcinoma of Head and Neck (1)

NCT	Acronym	Phase	Status	Title
NCT04465487	—	P1	terminated	Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

Advanced Malignant Skin Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT04387084	—	P1	active not recruiting	Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

HER2 Positive Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT04460456	—	P1	unknown	A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Recurrent Skin Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04315701	—	P2	active not recruiting	A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Metastatic Skin Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT04428671	—	P1	recruiting	Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Invasive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT04243616	CemiHALT	P2	active not recruiting	Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

HIV Infections (1)

NCT	Acronym	Phase	Status	Title
NCT03787095	—	P1/P2	terminated	Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

Metastatic Castration-Resistant Prostate Cancer (mCRPC) (1)

NCT	Acronym	Phase	Status	Title
NCT03972657	—	P1/P2	recruiting	A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Metastatic Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT03871348	—	P1	terminated	A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Advanced or Metastatic Merkel Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03684785	—	P1/P2	terminated	Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03769181	—	P1/P2	terminated	A Study of Isatuximab-based Therapy in Participants With Lymphoma

Squamous Cell Carcinoma of the Oropharynx (1)

NCT	Acronym	Phase	Status	Title
NCT03669718	—	P2	unknown	A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Relapsed Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT03690869	CNS	P1/P2	terminated	REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck (1)

NCT	Acronym	Phase	Status	Title
NCT03565783	—	P2	active not recruiting	Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Recurrent Ovarian Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03564340	—	P1/P2	recruiting	Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Squamous Cell Carcinoma (SCC) (1)

NCT	Acronym	Phase	Status	Title
NCT03257267	—	P3	completed	Study of Cemiplimab in Adults With Cervical Cancer

Carcinoma, Basal Cell (1)

NCT	Acronym	Phase	Status	Title
NCT03132636	—	P2	completed	PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Advanced Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT03233139	—	P1	active not recruiting	Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Malignant Solid Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT03192345	—	P1	completed	A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Carcinoma，Non-Small-Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT03088540	NSCLC	P3	completed	Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

B-Cell Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03017820	—	P1	recruiting	A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT03005782	—	P1	completed	Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Advanced Cutaneous Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02760498	—	P2	completed	Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Relapsed/Refractory Aggressive B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02651662	CLIO-1	P1	completed	A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

Advanced Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02383212	—	P1	completed	Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Breast Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT01042379	I-SPY	P2	recruiting	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Non-Small Cell Lung Cancer (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT06132191	—	N/A	approved for marketing	Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Cemiplimab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
REGN2810	NCT06568172	P3	suspended	Eyelid Squamous Cell Carcinoma	420	—
ARCH	NCT06931717	P3	recruiting	Non-Small Cell Lung Cancer	390	—
LIMITLESS	NCT05317858	P3	recruiting	Brain Tumor	30	—
NSCLC	NCT03088540	P3	completed	Carcinoma，Non-Small-Cell Lung	712	PMID 33581821
NEO-SURG	NCT06449313	P2	recruiting	Non-small Cell Lung Cancer Stage III	21	—
IMMUNOLIFE2	NCT07001618	P2	recruiting	NSCLC (Advanced Non-small Cell Lung Cancer)	162	—
META-1	NCT07360743	P2	not yet recruiting	Non Small Cell Lung Cancer (Squamous or Non Squamous)	275	—
SPORADIC	NCT06656598	P2	recruiting	Stage III NSCLC	152	—
I-SPY	NCT01042379	P2	recruiting	Breast Neoplasms	5,000	PMID 21796368
PALACE	NCT06917573	P2	recruiting	Non Small Cell Lung Cancer Metastatic	63	—
LAG-BOOST	NCT07223541	P2	recruiting	Clear Cell Renal Cell Carcinoma	72	—
NeoMatryx	NCT07387198	P2	not yet recruiting	Merkel Cell Carcinoma, Stage I	135	—
REGN2810	NCT07281417	P2	recruiting	Sinonasal Squamous Cell Carcinoma	108	—
NEOPECS	NCT06418724	P2	not yet recruiting	Locally Advanced Cutaneous Squamous Cell Carcinoma	27	—
CECYDE	NCT07418931	P2	not yet recruiting	Advanced Squamous Non-Small Cell Lung Cancer	108	—
RCC	NCT07188896	P2	recruiting	Advanced Renal Cell Carcinoma (aRCC)	120	—
CemiHALT	NCT04243616	P2	active not recruiting	Invasive Breast Cancer	36	—
HYPERBOLIC	NCT07274384	P2	not yet recruiting	NSCLC (Non-small Cell Lung Cancer)	74	—
PROSECCO	NCT07511036	P2	not yet recruiting	Melanoma	20	—
CSCC	NCT06384820	P2	withdrawn	Cutaneous Squamous Cell Carcinoma	0	—
NSCLC	NCT06465329	P2	recruiting	Non-Small Cell Lung Cancer	120	—
TNT	NCT07527325	P2	not yet recruiting	Melanoma (Skin)	35	—
ICARS	NCT06219317	P2	recruiting	NSCLC Stage IV	136	—
SWITCH	NCT06790602	P2	recruiting	Pancreatic Ductal Adenocarcinoma (mPDAC)	43	PMID 34375311
NACho	NCT07224022	P2	not yet recruiting	Colon Cancer	24	—
Cemited	NCT07264673	P2	recruiting	NSCLC	160	—
TOP 2301	NCT06385262	P2	suspended	Non Small Cell Lung Cancer	126	—
LAG-MAPS	NCT07234058	P2	not yet recruiting	Pleural Mesotheliomas	126	—
CEMI-first	NCT06981325	P2	recruiting	Basal Cell Carcinoma (BCC)	34	—
VIRO-25	NCT06463665	P2	recruiting	Advanced Non-squamous Non-small-cell Lung Cancer	142	—
REGN2810	NCT06900595	P2	recruiting	Locally Advanced Adrenal Cortical Carcinoma	48	—
EMPIRE	NCT07058012	P2	recruiting	Colo-rectal Cancer	79	—
DISCERN	NCT05878288	P2	active not recruiting	Cutaneous Squamous Cell Carcinoma	11	—
GAP Cemi	NCT07433673	P2	recruiting	Colon and Rectal Cancer	20	—
BRAVA PENILE	NCT07101822	P2	not yet recruiting	Penile Cancer	42	—
BRAVA VULVAR	NCT07101848	P2	not yet recruiting	Vulvar Cancers	42	—
NeoSTOP-IT	NCT06571708	P2	recruiting	Bladder Cancer	36	—
INTERVAL	NCT07085572	P2	recruiting	Adrenal Cortical Carcinoma	31	PMID 31644329
ENCEFALO	NCT06887088	P2	recruiting	Melanoma BRAF V600E/K Mutated	33	PMID 34986285
ATRA	NCT06528769	P2	recruiting	Leiomyosarcoma	16	—
MINIMA	NCT04988074	P2	recruiting	HPV-Related Squamous Cell Carcinoma	32	—
REGN2810	NCT06980038	P2	recruiting	Head and Neck Squamous Cell Carcinoma	44	—
TRIPL	NCT06865339	P2	recruiting	NSCLC	76	PMID 21531085
OCSCC	NCT06448026	P2	recruiting	Locally Recurrent Oral Cavity Squamous Cell Carcinoma	17	—
N-PLANC	NCT06918132	P2	recruiting	Lung Non-Small Cell Carcinoma	60	—
RAD-IO	NCT05401786	P2	active not recruiting	Carcinoma, Non-Small-Cell Lung	54	—
ICING	NCT04763616	P2	completed	Natural Killer/T-cell Lymphoma	37	PMID 40073374
CERPASS	NCT04050436	P2	active not recruiting	Cutaneous Squamous Cell Carcinoma	231	—
HPV	NCT04646005	P2	completed	Cervical Cancer	113	—
HNSCC	NCT04831450	P2	withdrawn	Head and Neck Squamous Cell Carcinoma	0	—

Terminated and withdrawn Cemiplimab trials (27)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT06568172suspendedTesting the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
NCT05929664suspendedCemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
NCT06384820withdrawnStudy of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
NCT05840770withdrawnCemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
NCT06385262suspendedTOP 2301: Neoadjuvant Chemo for NSCLC
NCT05729139withdrawnCemiplimab/Peg-Interferon-α in Advanced CSCC
NCT04046107withdrawnSafety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
NCT05538988withdrawnBIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma
NCT04982224terminatedStudy of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
NCT06052852terminatedStudy of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
NCT04373083withdrawnAnti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
NCT04913220terminatedA Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
NCT04465487terminatedStudy of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
NCT04916002terminatedA Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
NCT03871348terminatedA First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT04382898terminatedPRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
NCT05535023withdrawnPhase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
NCT03690869terminatedREGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
NCT04729725terminatedSAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
NCT03769181terminatedA Study of Isatuximab-based Therapy in Participants With Lymphoma
NCT04831450withdrawnPhase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT04242173terminatedCemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
NCT03684785terminatedIntratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
NCT04006119terminatedStudy of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
NCT03367819terminatedIsatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
NCT03787095terminatedSafety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART
NCT03580694terminatedStudy of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

All Cemiplimab trials (198)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07050186		Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma	P2	recruiting	15	Northwestern University	Aug 2025
NCT07365839	CLeAR	Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma	P1	not yet recruiting	20	Virginia Commonwealth University	Jul 2026
NCT05137054		A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments	P1	recruiting	317	Regeneron Pharmaceuticals	Aug 2022
NCT07567469		A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma	P1/P2	not yet recruiting	120	Regeneron Pharmaceuticals	Aug 2026
NCT06246916		A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)	P3	recruiting	560	Regeneron Pharmaceuticals	Sep 2024
NCT07195734		Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer	P2	recruiting	180	National Cancer Institute (NCI)	Apr 2026
NCT06449313	NEO-SURG	Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement	P2	recruiting	21	Georgetown University	Aug 2026
NCT07001618	IMMUNOLIFE2	Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer	P2	recruiting	162	Gustave Roussy, Cancer Campus, Grand Paris	Nov 2025
NCT07470489		Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer	P2	not yet recruiting	12	M.D. Anderson Cancer Center	Sep 2026
NCT07360743	META-1	Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels	P2	not yet recruiting	275	UNICANCER	Apr 2026
NCT06508463		Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma	P1	recruiting	21	Mayo Clinic	Jan 2024
NCT03017820		A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	P1	recruiting	99	Mayo Clinic	Apr 2017
NCT05785767	NSCLC	A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)	P2/P3	active not recruiting	850	Regeneron Pharmaceuticals	Jun 2023
NCT06656598	SPORADIC	Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer	P2	recruiting	152	Intergroupe Francophone de Cancerologie Thoracique	Nov 2025
NCT06623656		Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC	P2	recruiting	112	Weill Medical College of Cornell University	Feb 2025
NCT01042379	I-SPY	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	P2	recruiting	5,000	QuantumLeap Healthcare Collaborative	Mar 2010
NCT06917573	PALACE	PALACE: Cemiplimab Trial According to ctDNA Levels	P2	recruiting	63	Fundación GECP	Jul 2025
NCT05800015		A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer	P2/P3	active not recruiting	950	Regeneron Pharmaceuticals	Aug 2023
NCT05142189	LuCa-MERIT-1	Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer	P1	recruiting	320	BioNTech SE	Jun 2022
NCT07223411		Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma	—	recruiting	20	John Kirkwood	Nov 2025
NCT04428671		Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer	P1	recruiting	20	Emory University	May 2020
NCT05352672		Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma	P3	active not recruiting	1,546	Regeneron Pharmaceuticals	Jul 2022
NCT07223541	LAG-BOOST	Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma	P2	recruiting	72	University of Oklahoma	Jan 2026
NCT07346196		A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck	P2	not yet recruiting	90	University of Chicago	Feb 2027
NCT06568172	REGN2810	Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer	P3	suspended	420	National Cancer Institute (NCI)	Feb 2025
NCT07387198	NeoMatryx	Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab	P2	not yet recruiting	135	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Jun 2026
NCT05929664		Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery	P2	suspended	70	Thomas Jefferson University	Jul 2023
NCT07061379	PROMOTING	Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen	—	recruiting	144	IRCCS San Raffaele	Jul 2025
NCT07404332		5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors	P1	recruiting	35	Mohammed Milhem	Feb 2026
NCT06769698		A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	P2	recruiting	120	Regeneron Pharmaceuticals	Apr 2026
NCT07281417	REGN2810	Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma	P2	recruiting	108	National Cancer Institute (NCI)	Nov 2026
NCT06190951		A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma	P2	active not recruiting	151	Regeneron Pharmaceuticals	Sep 2024
NCT06418724	NEOPECS	Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma	P2	not yet recruiting	27	Melanoma and Skin Cancer Trials Limited	Jul 2026
NCT07418931	CECYDE	A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer	P2	not yet recruiting	108	Gruppo Oncologico Italiano di Ricerca Clinica	May 2026
NCT07188896	RCC	A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)	P2	recruiting	120	Brian Rini	Apr 2026
NCT06121180		Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma	P2	recruiting	32	H. Lee Moffitt Cancer Center and Research Institute	Nov 2024
NCT07020065		Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%	P2	recruiting	156	Swiss Cancer Institute	Apr 2026
NCT06651593		Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors	P2	recruiting	40	M.D. Anderson Cancer Center	Jul 2025
NCT04243616	CemiHALT	Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer	P2	active not recruiting	36	Medical College of Wisconsin	Mar 2020
NCT07281768		Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer	P2	not yet recruiting	66	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Jul 2026
NCT07274384	HYPERBOLIC	Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial	P2	not yet recruiting	74	Università Vita-Salute San Raffaele	Jan 2026
NCT06205836		Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer	P2	recruiting	44	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Jun 2024
NCT06469281	MUC16	A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers	P1	recruiting	90	Regeneron Pharmaceuticals	Aug 2024
NCT07511036	PROSECCO	PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma	P2	not yet recruiting	20	M.D. Anderson Cancer Center	Sep 2026
NCT03916627		Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients	P2	active not recruiting	65	Regeneron Pharmaceuticals	Jul 2019
NCT06384820	CSCC	Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)	P2	withdrawn	0	Regeneron Pharmaceuticals	Nov 2024
NCT06585410		Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma	P3	recruiting	369	Regeneron Pharmaceuticals	Jan 2025
NCT06465329	NSCLC	A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)	P2	recruiting	120	Regeneron Pharmaceuticals	Nov 2024
NCT06743581	Dupi-Cemi	Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer	N/A	not yet recruiting	24	Centre hospitalier de l'Université de Montréal (CHUM)	Feb 2025
NCT05608291		A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery	P3	active not recruiting	1,564	Regeneron Pharmaceuticals	Jan 2023
NCT06413680	BrILliance	A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body	P1/P2	recruiting	240	Regeneron Pharmaceuticals	Sep 2024
NCT07527325	TNT	Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma	P2	not yet recruiting	35	University of California, Irvine	Jul 2026
NCT06219317	ICARS	Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC	P2	recruiting	136	European Organisation for Research and Treatment of Cancer - EORTC	Jan 2025
NCT06790602	SWITCH	Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma	P2	recruiting	43	University of California, San Diego	May 2026
NCT07179315		A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment	P2	not yet recruiting	68	University of Chicago	Dec 2026
NCT07224022	NACho	Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer	P2	not yet recruiting	24	John Strickler, M.D.	Jul 2026
NCT06161441		A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery	P2	active not recruiting	195	Regeneron Pharmaceuticals	Jul 2024
NCT07264673	Cemited	A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.	P2	recruiting	160	Fondazione Ricerca Traslazionale	Apr 2025
NCT05840770		Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer	P2	withdrawn	0	City of Hope Medical Center	Apr 2025
NCT06385262	TOP 2301	TOP 2301: Neoadjuvant Chemo for NSCLC	P2	suspended	126	Duke University	Mar 2025
NCT06848088		A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment	P2	enrolling by invitation	48	Regeneron Pharmaceuticals	Apr 2025
NCT07234058	LAG-MAPS	Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma	P2	not yet recruiting	126	Intergroupe Francophone de Cancerologie Thoracique	Feb 2026
NCT06981325	CEMI-first	Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients	P2	recruiting	34	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Aug 2025
NCT06463665	VIRO-25	Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer	P2	recruiting	142	Genelux Corporation	Sep 2024
NCT06900595	REGN2810	Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer	P2	recruiting	48	National Cancer Institute (NCI)	Feb 2026
NCT07058012	EMPIRE	A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)	P2	recruiting	79	NSABP Foundation Inc	Apr 2026
NCT05878288	DISCERN	Deep sequencIng in Cutaneous Squamous CEll caRciNomas	P2	active not recruiting	11	Peter MacCallum Cancer Centre, Australia	May 2023
NCT06826768		A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC	P1	recruiting	60	M.D. Anderson Cancer Center	Jul 2025
NCT06931717	ARCH	A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy	P3	recruiting	390	ETOP IBCSG Partners Foundation	Jan 2026
NCT06412198		A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations	P1/P2	recruiting	31	M.D. Anderson Cancer Center	Aug 2024
NCT07433673	GAP Cemi	Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)	P2	recruiting	20	Columbia University	Aug 2026
NCT07101822	BRAVA PENILE	A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER	P2	not yet recruiting	42	Hospital Israelita Albert Einstein	Dec 2025
NCT07101848	BRAVA VULVAR	A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER	P2	not yet recruiting	42	Hospital Israelita Albert Einstein	Nov 2025
NCT07251413	CEMIQUID	Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma	P1/P2	recruiting	18	Instituto Oncológico Dr Rosell	Oct 2025
NCT06571708	NeoSTOP-IT	Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)	P2	recruiting	36	Columbia University	Aug 2025
NCT06616584		Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)	P2/P3	recruiting	378	SWOG Cancer Research Network	May 2025
NCT04989946		Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer	P1/P2	recruiting	60	University of Wisconsin, Madison	Dec 2021
NCT06787612		Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer	P2	recruiting	220	Regeneron Pharmaceuticals	May 2025
NCT05363319	CEMI-LUNG	An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe	—	recruiting	500	Regeneron Pharmaceuticals	Oct 2022
NCT06902376	NEO-COMBATXL	XL092 and Cemiplimab in BRAF WT Thyroid Cancer	P1	recruiting	12	UNC Lineberger Comprehensive Cancer Center	Jun 2025
NCT04543071		Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma	P2	recruiting	10	Gulam Manji	Nov 2020
NCT07085572	INTERVAL	Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer	P2	recruiting	31	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Sep 2025
NCT06444880		Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies	P2	recruiting	40	M.D. Anderson Cancer Center	Oct 2024
NCT05729139		Cemiplimab/Peg-Interferon-α in Advanced CSCC	P1	withdrawn	0	Baptist Health South Florida	Jul 2023
NCT05557591		A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)	P2	active not recruiting	51	Regeneron Pharmaceuticals	Apr 2023
NCT06943664		Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer	P2	not yet recruiting	27	Roswell Park Cancer Institute	May 2026
NCT05961709		The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer	P2	active not recruiting	50	M.D. Anderson Cancer Center	May 2024
NCT06923761	EMITT-1	EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)	P1/P2	recruiting	300	Grey Wolf Therapeutics	May 2023
NCT07414992		A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer	P2	not yet recruiting	44	Memorial Sloan Kettering Cancer Center	May 2026
NCT06855212		Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC	P2	active not recruiting	22	H. Lee Moffitt Cancer Center and Research Institute	Feb 2025
NCT04975152		Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma	P1	recruiting	36	H. Lee Moffitt Cancer Center and Research Institute	Oct 2021
NCT06699602		A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma	P2	recruiting	10	Memorial Sloan Kettering Cancer Center	Feb 2025
NCT06384807		A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors	P1/P2	recruiting	500	Biohaven Therapeutics Ltd.	Apr 2024
NCT06887088	ENCEFALO	Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases	P2	recruiting	33	Grupo Español Multidisciplinar de Melanoma	May 2025
NCT03969004		Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma	P3	active not recruiting	415	Regeneron Pharmaceuticals	Jun 2019
NCT06731270		Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy	P2	recruiting	20	Emory University	Apr 2025
NCT05704634		A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.	P1	active not recruiting	56	M.D. Anderson Cancer Center	Aug 2023
NCT06908304		A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC	P3	recruiting	300	Maia Biotechnology	Dec 2025
NCT06528769	ATRA	Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma	P2	recruiting	16	Gabriel Tinoco	Sep 2025
NCT05208944		THIO Sequenced With Cemiplimab in Advanced NSCLC	P2	active not recruiting	227	Maia Biotechnology	Jun 2022
NCT04988074	MINIMA	Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca	P2	recruiting	32	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Dec 2021
NCT04315701		A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer	P2	active not recruiting	35	University of Southern California	Jun 2020
NCT03565783		Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery	P2	active not recruiting	44	M.D. Anderson Cancer Center	Jul 2018
NCT07450183		Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1	P2	not yet recruiting	33	Henry Ford Health System	Jun 2026
NCT05317858	LIMITLESS	Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets	P3	recruiting	30	InSightec	Aug 2022
NCT04590326		A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab	P1/P2	recruiting	612	Regeneron Pharmaceuticals	Dec 2020
NCT06980038	REGN2810	Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer	P2	recruiting	44	National Cancer Institute (NCI)	May 2026
NCT03972657		A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors	P1/P2	recruiting	345	Regeneron Pharmaceuticals	Aug 2019
NCT07147231	CX-5461	Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer	P1/P2	recruiting	86	National Cancer Institute (NCI)	Dec 2026
NCT06594991		A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma	P2	recruiting	88	Memorial Sloan Kettering Cancer Center	Sep 2024
NCT04046107		Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy	P1/P2	withdrawn	0	National Institute of Allergy and Infectious Diseases (NIAID)	Jan 2024
NCT03233139		Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies	P1	active not recruiting	146	Regeneron Pharmaceuticals	Jun 2017
NCT06865339	TRIPL	Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer	P2	recruiting	76	Montefiore Medical Center	Aug 2025
NCT04387084		Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy	P1	active not recruiting	10	University of Southern California	Aug 2020
NCT06162572	NSCLC	Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)	P1/P2	active not recruiting	102	Servier Bio-Innovation LLC	Aug 2024
NCT07064330	NGF-GRACE	Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.	—	recruiting	30	Instituto de Investigación Biomédica de Salamanca	Jul 2025
NCT06171750	ANCHOR	Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors	P1	recruiting	97	Ankyra Therapeutics, Inc	Jan 2024
NCT05864144		A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors	P1/P2	active not recruiting	98	Sensei Biotherapeutics, Inc.	May 2023
NCT04305795		An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors	P1/P2	active not recruiting	23	Rakuten Medical, Inc.	Dec 2020
NCT05694871		Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma	P2	active not recruiting	77	Alliance for Clinical Trials in Oncology	Jun 2023
NCT06448026	OCSCC	Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).	P2	recruiting	17	M.D. Anderson Cancer Center	Nov 2024
NCT03564340		Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers	P1/P2	recruiting	890	Regeneron Pharmaceuticals	May 2018
NCT06918132	N-PLANC	Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer	P2	recruiting	60	Mayo Clinic	Apr 2025
NCT06088771		Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC	P1/P2	recruiting	21	Icahn School of Medicine at Mount Sinai	Mar 2024
NCT04626635	COMBINE-EGFR-1	A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers	P1/P2	recruiting	933	Regeneron Pharmaceuticals	Dec 2020
NCT06302426		Trial of INI-4001 in Patients With Advanced Solid Tumours	P1	recruiting	50	Inimmune Corporation	Jul 2024
NCT07422363	REGN2810	Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma	P1	not yet recruiting	30	National Cancer Institute (NCI)	Jun 2026
NCT06090266		A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents	P1/P2	recruiting	168	OncoResponse, Inc.	Oct 2023
NCT05501665		Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer	P1/P2	recruiting	25	Vanderbilt-Ingram Cancer Center	May 2023
NCT06860815		Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer	P2	recruiting	11	City of Hope Medical Center	Jan 2026
NCT05259709		A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab	P1	recruiting	50	Regeneron Pharmaceuticals	Feb 2023
NCT05662397		A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody	P1/P2	active not recruiting	77	HotSpot Therapeutics, Inc	Mar 2023
NCT04862650		Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	P2	active not recruiting	46	Marcelo Bonomi	Nov 2021
NCT03491683	EP	INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)	P1/P2	active not recruiting	52	Inovio Pharmaceuticals	May 2018
NCT05669989		International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab	P2	active not recruiting	70	Sanofi	Apr 2023
NCT05553834		PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung	P2	active not recruiting	60	Duke University	May 2023
NCT05574101		A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer	P2	active not recruiting	34	Memorial Sloan Kettering Cancer Center	Oct 2022
NCT06532149	EROS	ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer	—	recruiting	80	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Aug 2024
NCT05882734	M1774	Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)	P1/P2	active not recruiting	61	EMD Serono Research & Development Institute, Inc.	Sep 2023
NCT06022029	ON-5001	A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.	P1	recruiting	168	OncoNano Medicine, Inc.	Oct 2023
NCT05401786	RAD-IO	Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC	P2	active not recruiting	54	The Netherlands Cancer Institute	Jan 2023
NCT04722523		A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer	P1	recruiting	40	Memorial Sloan Kettering Cancer Center	Jan 2021
NCT02651662	CLIO-1	A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies	P1	completed	105	Regeneron Pharmaceuticals	Jan 2016
NCT04763616	ICING	Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy	P2	completed	37	Won Seog Kim	Jun 2021
NCT05538988	BIOSELECT	BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma	P1/P2	withdrawn	0	AHS Cancer Control Alberta	Dec 2024
NCT04632433		Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma	P2	active not recruiting	25	Fondazione Melanoma Onlus	Feb 2021
NCT04291105		Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients	P2	recruiting	87	Vyriad, Inc.	Apr 2020
NCT03889912		Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma	P1	completed	97	Regeneron Pharmaceuticals	Apr 2019
NCT04706715		LAG3 PET Imaging in Advanced Solid Tumors	P1/P2	active not recruiting	41	University Medical Center Groningen	Jan 2022
NCT04526899		A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment	P2	completed	184	BioNTech SE	May 2021
NCT04154943		Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma	P2	completed	79	Regeneron Pharmaceuticals	Mar 2020
NCT05376553		Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck	P1	enrolling by invitation	24	Krzysztof Misiukiewicz	Jul 2022
NCT04982224	MET	Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer	P1	terminated	30	Regeneron Pharmaceuticals	Nov 2021
NCT04050436	CERPASS	Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer	P2	active not recruiting	231	Replimune, Inc.	Oct 2019
NCT03836105	CASE	CemiplimAb Survivorship Epidemiology	—	completed	287	Regeneron Pharmaceuticals	Jun 2019
NCT06052852		Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies	P1	terminated	17	Bolt Biotherapeutics, Inc.	Oct 2023
NCT03669718		A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC	P2	unknown	194	ISA Pharmaceuticals	Nov 2018
NCT03088540	NSCLC	Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)	P3	completed	712	Regeneron Pharmaceuticals	May 2017
NCT05064085		Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer	P1	completed	13	H. Lee Moffitt Cancer Center and Research Institute	Oct 2021
NCT04339062	CONTRAC	Cemiplimab in AlloSCT/SOT Recipients With CSCC	P1/P2	completed	12	Dana-Farber Cancer Institute	Nov 2020
NCT04373083		Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma	P2	withdrawn	0	Regeneron Pharmaceuticals	Nov 2020
NCT04913220		A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)	P1/P2	terminated	46	Sanofi	Jul 2021
NCT04465487		Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies	P1	terminated	38	Regeneron Pharmaceuticals	Oct 2020
NCT04679480		Anti-PD1-antibody and Pulsed HHI for Advanced BCC	P2	active not recruiting	20	Reinhard Dummer	Feb 2021
NCT04916002		A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer	P2	terminated	77	Regeneron Pharmaceuticals	Nov 2021
NCT05259696	GLIMMER-01	Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)	P1/P2	completed	69	Palleon Pharmaceuticals, Inc.	Feb 2022
NCT04873375		Cemiplimab for Secondary Angiosarcomas	P2	completed	18	Radboud University Medical Center	Jan 2022
NCT05094804		A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	P1/P2	unknown	172	OncoResponse, Inc.	Sep 2021
NCT05967884		PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer	P2	unknown	20	Ottawa Hospital Research Institute	Aug 2023
NCT05054348		First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors	P1	completed	91	Immune-Onc Therapeutics	Sep 2021
NCT04646005	HPV	Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy	P2	completed	113	Regeneron Pharmaceuticals	Jun 2021
NCT03005782		Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers	P1	completed	333	Regeneron Pharmaceuticals	Nov 2016
NCT03871348		A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors	P1	terminated	77	Sanofi	Jan 2019
NCT04382898	PRO-MERIT	PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)	P1/P2	terminated	75	BioNTech SE	Dec 2019
NCT04826393		ASP8374 + Cemiplimab in Recurrent Glioma	P1	completed	14	Dana-Farber Cancer Institute	Mar 2022
NCT03294083		A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma	P1/P2	active not recruiting	89	SillaJen, Inc.	Jun 2018
NCT06132191		Expanded Access Use of Cemiplimab in Patients With Solid Tumors	—	approved for marketing	0	Regeneron Pharmaceuticals	—
NCT02760498		Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma	P2	completed	432	Regeneron Pharmaceuticals	Apr 2016
NCT05535023		Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma	P2	withdrawn	0	M.D. Anderson Cancer Center	Aug 2022
NCT04177810		Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer	P2	completed	25	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Nov 2020
NCT03690869	CNS	REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma	P1/P2	terminated	57	Regeneron Pharmaceuticals	Sep 2018
NCT03132636		PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy	P2	completed	138	Regeneron Pharmaceuticals	Jun 2017
NCT03257267		Study of Cemiplimab in Adults With Cervical Cancer	P3	completed	608	Regeneron Pharmaceuticals	Sep 2017
NCT03194867	RRMM	Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients	P1/P2	completed	109	Sanofi	Feb 2018
NCT04460456		A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors	P1	unknown	58	Silverback Therapeutics	Jul 2020
NCT04729725		SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL	P1	terminated	3	M.D. Anderson Cancer Center	Feb 2021
NCT03769181		A Study of Isatuximab-based Therapy in Participants With Lymphoma	P1/P2	terminated	58	Sanofi	Dec 2018
NCT05302297	TOSCA	Comparative Efficacy of Cemiplimab to Historical Standard of Care in France	—	completed	305	Sanofi	Jan 2022
NCT04831450	HNSCC	Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)	P2	withdrawn	0	University of Miami	Jul 2022
NCT04242173		Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC	P2	terminated	3	H. Lee Moffitt Cancer Center and Research Institute	Jun 2020
NCT03684785		Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors	P1/P2	terminated	57	Exicure, Inc.	Dec 2018
NCT03192345		A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors	P1	completed	161	Sanofi	Jun 2017
NCT04006119		Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma	P2	terminated	40	Alaunos Therapeutics	Aug 2019
NCT03367819		Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies	P1/P2	terminated	44	Sanofi	Jan 2018
NCT03787095		Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART	P1/P2	terminated	5	National Institute of Allergy and Infectious Diseases (NIAID)	Aug 2019
NCT03580694	NSCLC	Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	P1	terminated	17	Regeneron Pharmaceuticals	Jun 2018
NCT02383212		Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies	P1	completed	398	Regeneron Pharmaceuticals	Feb 2015
NCT03492489		Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma	—	no longer available	0	Regeneron Pharmaceuticals	—

Cemiplimab clinical trials: frequently asked questions

How many Cemiplimab clinical trials are there?: 198 Cemiplimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 84 are actively recruiting participants. 23 are marked completed.
Are Cemiplimab clinical trials recruiting in 2026?: Yes — 84 Cemiplimab trials are actively recruiting in 2026, with 937 U.S. sites across 49 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Cemiplimab being studied for?: Cemiplimab is being studied for Cutaneous Squamous Cell Carcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer and 382 more. The trials are grouped by indication on this page.
What phase is Cemiplimab in?: Cemiplimab clinical trials span 11 Phase 3, 101 Phase 2, 37 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Cemiplimab clinical trials?: The lead sponsor across the most Cemiplimab trials is Regeneron Pharmaceuticals, with 100 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Cemiplimabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Cemiplimab overview Cemiplimab evidence & publications